1996

(BW) Matrix Receives FDA Action Letter on AccuSite: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Tuesday, 24 December 1996.; FREMONT, Calif.--(BUSINESS WIRE)--Dec. 24, 1996--Matrix Pharmaceutical, Inc. (NASDAQ/NMS: MATX) today announced that it received an action letter from the U.S. Food and Drug Administration ( FDA ) late Monday afternoon identifying issues that will need to be resolved before the Company s New Drug Application (NDA) for
(BW) (TIME-MAGAZINE/HO) ADVANCE/Statement from TIME Man of the Year David D. Ho, MD: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 21 December 1996.; (ADVANCE) NEW YORK--(BUSINESS WIRE)--Dec. 21, 1996--The following is a statement from TIME Man of the Year David D. Ho, MD, Scientific Director, Aaron Diamond AIDS Research Center Professor, The Rockefeller University: My colleagues and I are greatly appreciative of this recognition. Achievements in research do not bel
(BW) (TIME-MAGAZINE) ADVANCE/AIDS Researcher David Ho is TIME's Man of the Year; Pioneering Treatment Offers Potential Hope for Thousands of AIDS Patients: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Saturday, 21 December 1996.; (ADVANCE) NEW YORK--(BUSINESS WIRE)--Dec. 21, 1996--Pioneering AIDS researcher Dr. David D. Ho, whose novel use of a cocktail of protease inhibitors and other antiviral drugs in the earliest stages of infection has shown remarkable promise in beating back the AIDS virus, is TIME Magazine s 1996 Man of the Year. Wh
(BW) (LAWSUIT/DIGNITY-PARTNERS) Class Action Suit Filed Against Dignity Partners, Inc. And Its Officers And Directors Alleging Misrepresentations And False Financial Statements: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 19 December 1996.; SAN DIEGO--(BUSINESS WIRE)--Dec. 19, 1996--A class action has been commenced in the United States District Court for the Northern District of California by plaintiffs Howard Hertzberg, John DeRosa and Jeffrey Feinman on behalf of purchasers of Dignity Partners, Inc. ( Dignity ) common stock during the period February 1
(BW) New Research Shows HIV Can Be Eliminated In Lymphatic Tissue: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Tuesday, 17 December 1996.; SAN FRANCISCO--(BUSINESS WIRE)--Dec. 17, 1996--On Monday December 16, at 6:30pm, Dr. Roger Mills, Medical Director, Antiviral Venture at Abbott Laboratories will review data he recently presented at the 3rd International Congress on Drug therapy in HIV Infection, in Birmingham, England. The subject of Dr. Mill s re
(BW) (CHIRON)(CHIR) Chiron to License RPR for HSV-tk Gene and Cross-License Technologies with Ciba -- Novartis: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Tuesday, 17 December 1996.; EMERYVILLE, Calif.--(BUSINESS WIRE)--Dec. 17, 1996--Chiron Corp. (NASDAQ:CHIR) announced today that it has agreed to grant royalty- bearing licenses to its patents for the HSV-tk ( herpes simplex virus -- thymidine kinase) gene for use in gene therapy, in conjunction with a consent and agreement that resolves the Feder
(BW) (INNOVIR)(INVR) Innovir's EGS Oligozyme Technology shows promising results in combating Hepatitis B in cell and animal models: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Tuesday, 17 December 1996.; NEW YORK--(BUSINESS WIRE)--Dec. 17, 1996-- Early Indications Suggest Oligozyme Is More Potent Than 3TC Hepatitis B Is Widespread Disease With No Broadly-Accepted Therapy Speaking at the Sixth Anti-Sense Conference earlier this month in Tsukuba Science City, Japan , Allan Goldberg, Cha
(BW) (FEMALE-HEALTH-CO)(FHC) Female Health Co. to distribute female condoms in Taiwan: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Monday, 16 December 1996.; CHICAGO--(HealthWire)--Dec. 16, 1996--The Female Health Co. announced today that it has signed an agreement with a major Taiwanese pharmaceutical group Chung Mei Enterprises for the exclusive distribution of the company s female condom in Taiwan. The new agreement was announced in Taipei by Chung Mei Enterprises during
(BW) (NAMES-PROJECT) NAMES Project Foundation Elects Three New Board Members; Julie Stachowiak, Kevin Allen and Clarissa Crabtree Bring Diverse Range of Experience to the NAMES Project Foundation: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Monday, 16 December 1996.; SAN FRANCISCO--(BUSINESS WIRE)--Dec. 16, 1996--Three new members were elected to the NAMES Project Foundation s board of directors on November 23. The newest members -- Julie Stachowiak, Kevin Allen and Clarissa Crabtree -- bring a range of experience in public health and substance abuse issues, international AIDS effo
(BW) (BIOMED-COMM-INC) U.S. Patent allowance awarded to new alternative medicine new technology; includes cost-efficient AIDS medicines: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Friday, 13 December 1996.; SEATTLE--(BUSINESS WIRE)--Dec. 13, 1996--U.S. Patent Notice of Allowance on a new alternative medicine was awarded to Biomed Comm Inc., Seattle. It is the first company to patent homeopathic growth factors for use as an alternative medicine, developed by Dr. Barbara Brewitt, Biomed chief scientific officer. In 1995, Br
(BW) (UCSF) Gladstone Institute Researchers Identify One of the Molecular Mechanisms that Allows HIV to Enter Human Cells: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Thursday, 12 December 1996.; SAN FRANCISCO--(BUSINESS WIRE)--Dec. 12, 1996--In a study that helps to explain how the human immunodeficiency virus (HIV) enters human cells, Gladstone Institute researchers have identified the docking sites allowing the virus to attach to one of the receptors or ports of entry into the cell. The researchers reported
(BW) Procept initiates Phase I clinical trial of topical microbicide: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Monday, 9 December 1996 - 7:28 A.M. EDT; CAMBRIDGE, Mass.,--(BUSINESS WIRE)--Dec. 9, 1996-- Procept Inc announced today that it has initiated a Phase I clinical trial of its PRO 2000 topical microbicide in Antwerp, Belgium with dosing to begin in January. The intravaginally applied gel is designed to protect women from HIV infection and other sexually transmi
(BW) AmBisome, DaunoXome Data Presented At American Hematology Society meeting: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Friday, 6 December 1996.; BOULDER, Colo.--(BUSINESS WIRE)--Dec. 6, 1996--NeXstar Pharmaceuticals Inc. (NASDAQ:NXTR) announced that independent research groups will present data this weekend on the Company s two products, AmBisome and DaunoXome, at the 38th Annual Meeting of the American Society of Hematology. DaunoXome, the Company s liposomal
(BW) (GEN-PROBE-INC) ADVISORY/United States takes major step toward meeting safe blood supply goal: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Friday, 6 December 1996.; --(BUSINESS WIRE)-- Federal government issues $7.7 million contract to put improved screening system for HIV and hepatitis C in place within three years *T WHAT: Although our nation s blood supply is the safest it s ever been, Americans are still at risk of receiving a blood transfusion containing undetected H
(BW) State Board of Health to discuss drinking water, telemedicine, HIV/AIDS legislation and regulation of surgical technologists: BUSINESS WIRE; Thursday, 5 December 1996.; OLYMPIA, Wash.--(BUSINESS WIRE)--Dec. 5, 1996--The state Board of Health will meet Dec. 11 to discuss telemedicine, amendments to the Federal Safe Drinking Water Act, a change in HIV/AIDS legislation, and regulation of surgical technologists. The meeting is open to the public. It will take place from 9 a.m. to 5 p.m. a
(BW) (HYCOR-BIOMEDICAL)(HYBD) Hycor Biomedical Introduces New Diagnostic Instrument System: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Thursday, 5 December 1996.; IRVINE, Calif.--(BUSINESS WIRE)--Dec. 5, 1996--Hycor Biomedical Inc. (NASDAQ:HYBD) introduced its new HY-TEC 288(TM), the latest addition to the line of fully automated immunoassay systems for both allergy and autoimmune testing at Medica 96, the international medical trade fair in Dusseldorf, Germany .
(BW) New UCSF Program Combines "Alternative" Medicine and Latest Scientific Advances: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Wednesday, 4 December 1996.; SAN FRANCISCO--(BUSINESS WIRE)--Dec. 4, 1996--A new UCSF Program in Integrative Medicine promises to combine the traditional knowledge of ancient Eastern medicine, lifestyle and nutritional changes, and other alternative treatments with the latest laboratory breakthroughs in a comprehensive effort to educate doctors, t
(BW) HOME-ACCESS-HEALTH) Home Access Health announces retail agreement with American Stores Company: BUSINESS WIRE; Monday, 2 December 1996.; HOFFMAN ESTATES, Ill.--(HealthWire)--Dec. 2, 1996-- Home Access Expands National OTC Availability for HIV-1 Home Test Option Home Access Health Corporation announced a retail distribution agreement with American Stores Company (NYSE:ASE), one of the nation s largest food and drug retailers. The Home Access(TM) and Home
(BW) Galagen Announces Promising Phase I/II Clinical Results for Sporidin-G in the Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Monday, 2 December 1996, 5:30 Pacific; ARDEN HILLS, Minn.--(HealthWire)--December 2, 1996-- Product Shows Potential as Treatment for AIDS-Related Diarrhea GalaGen Inc. (Nasdaq: GGEN) today announced that use of its lead product in development, Sporidin-G(TM), showed favorable clinical results and an acceptable safety profile in the treatment of diarrhea cau
(BW) (UCSF/AIDS-RESEARCH) ADVANCE/AIDS Patients on Growth Hormone Gain Significant Amount of Lean Tissue, Perform Better on Treadmill Tests, UCSF Study Finds: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Saturday, 30 November 1996; ADVANCE...for release 5 p.m. EST Nov. 30 (ADVANCE) SAN FRANCISCO--(BUSINESS WIRE)--Nov. 30, 1996--AIDS patients who took daily injections of human growth hormone gained a significantly greater amount of weight, particularly lean body mass, than patients on placebo, according to the results of a newly published multicen
(BW) (CONANT-FOUNDATION) Access to Treatment Information is Our Best Weapon in the AIDS Crisis: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Friday, 29 November 1996.; SAN FRANCISCO--(BUSINESS WIRE)--Nov. 29, 1996--While there have never been more treatments available for people living with HIV disease, the need to understand these options has never been greater. The average cost of treatment with a three drug combination therapy is more than $15,000 annually. The Marcus A. Conan
(BW) (FEDERATED-DEPT-STORES)(FD) Federated gives $2 million to AIDS causes nationwide: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Friday, 29 November 1996, 5:00 P.M.; CINCINNATI--(BUSINESS WIRE)--Nov. 29, 1996--Department Store Divisions Are United in Grants & Volunteer Efforts In commemoration of World AIDS Day on Dec. 1, Federated Department Stores, Inc. announced today that corporate and division contributions made nationally to projects and organizations dedicated to HIV/AID
(BW) (GA-DEPT-OF-HUMAN-RESOUR) Aids Update: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Wednesday, 27 November 1996.; ATLANTA--(BUSINESS WIRE)--Nov. 27, 1996--Cumulative number of AIDS cases in Georgia since 1981, as reported to the Department of Human Resources, Division of Public Health, Epidemiology and Prevention Branch, AIDS Surveillance. -0- *T Reported as of October 31, 1996 CASES DEATHS Adults 16,412 Adul
(BW) (HOME-ACCESS/AIDS/MTV) Home Access Health sponsors World AIDS Day programming on MTV and VH1: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Tuesday, 26 November 1996.; HOFFMAN ESTATES, Ill.--(HealthWire)--Nov. 26, 1996--Home Access Health Corporation, which markets the Home Access(TM) and Home Access Express(TM) HIV-1 test systems, will be the exclusive sponsor of special World AIDS Day programming on MTV and VH1, Sunday, December 1. In addition to on-air sponsorship mentions and com
(BW) North American Vaccine Announces Update On FDA Advisory Committee Meeting: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Tuesday, 26 November 1996.; BELTSVILLE, Md.--(BUSINESS WIRE)--Nov. 26, 1996--North American Vaccine (AMEX:NVX) maintains its policy of not commenting on interactions with the U.S. Food and Drug Administration ( FDA ) in, or the status of, the FDA s review of the company s products or on rumors or press reports appearing in the media regarding the
(BW) (BENEFIT-ADVOCATES) The rise, fall and resurrection of an industry: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Tuesday, 26 November 1996.; LOS ANGELES--(BUSINESS WIRE)--Nov. 26, 1996--An industry with a primary focus on providing services to people living with AIDS in the late 1980s is now reinventing itself. The advent of miracle drugs called protease inhibitors has lengthened life expectancies for people living with HIV and AIDS. In turn, the viatical s
(BW) (NAMES-PROJECT/QUILT/AOL) First Online Display of the Quilt takes place Dec. 1 on America Online; World AIDS Day Will Mark First Display of AIDS Memorial Quilt Held in Cyberspace: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Monday, 25 November 1996.; SAN FRANCISCO--(BUSINESS WIRE)--Nov. 25, 1996--In observance of World AIDS Day, the NAMES Project Foundation will launch the first-ever online display of the AIDS Memorial Quilt on Dec. 1, 1996. The on-line display will feature six Quilt sections that include 48 individual memorial panels commemorating the lives of ind
(BW) AIDS Quilt will be on display at three State Street Bank and Trust Company offices: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Monday, 25 November 1996.; BOSTON--(BUSINESS WIRE)--Nov. 25, 1996-- On Tuesday, Nov. 26, State Street Bank and Trust Company will exhibit panels of the AIDS Memorial Quilt in the lobbies of three of its buildings in honor of the ninth-annual international observance of World AIDS Day, Dec. 1. World AIDS Day is an event designed to strengthen and
(BW) Nonoxynol-9 Products Discussed At FDA Advisory Committee Meeting, Including Columbia Laboratories' Advantage 24: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Monday November 25 8:27 AM EDT; MIAMI--(BUSINESS WIRE)--Nov. 25, 1996-- -- Advantage 24 Effectiveness Studies Ongoing In International Phase III Clinicals Utilizing Design Recommended By FDA Committees -- Columbia Laboratories Inc today reported that at a meeting of the U.S. Food and Drug Administration s Nonprescription Drugs, Reproductive Health Dr
(BW) (SUPERGEN/GALENICA)(SUPG)(SUPGW) SuperGen and Galenica Pharmaceuticals announce anticancer collaboration: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Monday, 25 November 1996.; EMERYVILLE, Calif.--(BUSINESS WIRE)--Nov. 25, 1996--SuperGen Inc. (NASDAQ: SUPG & SUPGW) and Galenica Pharmaceuticals Inc., both emerging pharmaceutical companies, announced they have agreed to a strategic collaboration aimed at the discovery and development of new anticancer drugs based on natural products. SuperG
(BW) Tularik Announces Advances in Patent Position Covering Novel Screening Assays and Key Therapeutic Targets: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Thursday, 21 November 1996.; SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 21, 1996-- Tularik Inc. today announced the issuance of two U.S. Patents, No. 5,563,036 covering the development and use of novel in vitro transcription factor binding assays, and No. 5,563,039, covering a key component of the tumor necrosis factor (TNF) signaling path
(BW) Study Shows Effectiveness Of Crypto-Scan To Detect Cryptosporidium And Other Microbes In Drinking Water: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Wednesday, 20 November 1996.; PORTLAND, Maine--(BUSINESS WIRE)--Nov. 20, 1996-- Current methods to detect Cryptosporidium are time-consuming, often inefficient and highly variable. Crypto-Scan consistently showed a recovery rate of more than 50 percent in both raw and finished water. With this type of test, the entire process can be done in just on
(BW) India Group signs SALV contract for rapid HIV tests: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Tuesday, 19 November 1996.; VANCOUVER, Wash.--(BUSINESS WIRE)--Nov. 19, 1996--Saliva Diagnostic Systems Inc. (SDS) (NASDAQ: SALV) announced Tuesday that the Fremont Novo Sciences of Chicago today signed a contract to purchase at least 250,000 of SDS rapid HIV tests, and agreed to pay SDS a licensing fee for exclusive distribution rights within
(BW) Majority Of Doctors Feel Research Money Should Be Split Between Treatment & Early Detection/prevention: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Monday, 18 November 1996.; (ADVANCE) NEW YORK--(BUSINESS WIRE)--Nov. 18, 1996-- 39 percent opt for prevention research, compared to four percent favoring treatment 24 percent of doctors believe too much being spent on AIDS research. Though a majority of American doctors (55%) believe medical research money should be equally divided between treat
(BW) (BEACON-DIAGNOSTICS) Beacon Diagnostics Launches Saliva-Based OraScreen HIV Rapid Test in the Caribbean; Company Also Signs Manufacturing Agreement in Preparation for U.S. Trials: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Monday, 18 November 1996.; FOSTER CITY, Calif--(BUSINESS WIRE)--Nov. 18, 1996--Beacon Diagnostics Inc., an emerging developer of non-invasive diagnostics, today announced that it has begun marketing its first product, OraScreen HIV Rapid Test, for detection of antibodies to HIV in saliva, in the Caribbean. The test is being sold by Beacon s regi
(BW) (HOME-ACCESS/WALGREENS) Home Access Express HIV-1 Test System available at Walgreens: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Monday, 18 November 1996.; HOFFMAN ESTATES, Ill.--(HealthWire)--Nov. 18, 1996--The nation s largest retail drug store chain is now selling Home Access Health Corporation s Home Access Express(TM) HIV-1 Test System over-the-counter, the company announced. Home Access Express(TM) is available at nearly 2,200 Walgreens drug stores in 34 states acro
(BW) (SPECIALIZED-HEALTH)(SHPI) Specialized Health Products International, Inc. announces allowance of its sixth needle withdrawal patent: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Monday, 18 November 1996.; BOUNTIFUL, Utah --(BUSINESS WIRE)--Nov. 18, 1996--Specialized Health Products International, Inc. (NASDAQ: SHPI) today announced its wholly-owned subsidiary, Specialized Health Products ( SHP ), received its sixth needle withdrawal patent relating to SHP s proprietary ExtreSafe(tm) medical needle withdrawal and contain
(BW) Report Examines Importance of Medical Gloves, Condoms: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Friday, 15 November 1996.; MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Nov. 15, 1996--The market for disposable medical gloves has grown as the medical community seeks protection from blood contamination, while the market for condoms has softened, according to research by Frost & Sullivan. The study, U.S. DISPOSABLE MEDICAL GLOVES AND CONDOM MAR
(BW) AIDS Research to Focus on Management, Therapy: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Friday, 15 November 1996.; MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Nov. 15, 1996--Although the spread of AIDS has slowed to 5 percent annual growth, the market to treat and research the virus is burgeoning, according to research by Frost & Sullivan. Industry revenues of $1.3 billion in 1995 are expected to at least double by 2002, according
(BW) Institute of Human Virology Officially Opens With `A Celebration of Biological Science'; Historic Gathering of 20th-Century Life-Sciences Luminaries Convenes in Baltimore for Two-Day Meeting: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Thursday, 14 November 1996.; BALTIMORE, Nov. 14 /PRNewswire/ -- A constellation of some of the world s most distinguished scientists, representing every major field of biological research, will convene in Baltimore on November 18 and 19 to reflect on the phenomenon of biological discovery in the 20th century and speculate on potential directions f
(BW) Research into Peptide Therapy Offers Hope for Millions of Americans: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Wednesday, 13 November 1996.; MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Nov. 13, 1996--Medical research into hormonal analogous treatments -- peptide therapy -- is expanding to encompass an array of diseases, according to Frost & Sullivan. In its analysis, U.S. MARKET FOR SYNTHETICALLY DERIVED THERAPEUTIC PEPTIDES, the marketing consulting firm a
(BW) (FROST-&-SULLIVAN-13) Autoimmune Disease Sufferers, Research Firms Would Benefit from Development of Medications: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Wednesday, 13 November 1996.; MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Nov. 13, 1996-- Americans suffering from autoimmune diseases are dissatisfied with medications currently on the market and are demanding new treatments that do more than relieve symptoms, according to research by Frost & Sullivan. U.S. AUTOIMMUNE DISEASE THERAPEUTIC MARKETS r
(BW) Employers' Health Purchasing Co-op Announces Statewide Expansion, Enhanced Benefits And New Health Plans: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Wednesday, 13 November 1996; SEATTLE--(BUSINESS WIRE)--Nov. 13, 1996--The Employers Health Purchasing Co-op (EHPC) today announced that it will offer coverage throughout Washington state, coverage to employers with as few as two employees, and coverage to domestic partners of covered employees (for companies with 25 or more employees). These chang
(BW) (SEQUUS-PHARM)(SEQU) SEQUUS Pharmaceuticals announces registration-oriented clinical trials of DOXIL in ovarian cancer patients: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Wednesday, 13 November 1996.; MENLO PARK, Calif.--(BUSINESS WIRE)--November 13, 1996--SEQUUS Pharmaceuticals Inc. (NASDAQ:SEQU) today announced that a series of clinical trials of DOXIL (R) (doxorubicin HC1 liposome injection) is underway in ovarian cancer patients. These studies are part of the company s clinical development plan and registration
(BW) Ophthalmic Pharmaceutical Envisions Growth In New Products, Therapies: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Tuesday, 12 November 1996.; MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Nov. 12, 1996--Foresight is crucial for the ophthalmic pharmaceutical market if it is to remain focused on worldwide growth. There are some significant technological changes occurring in the market, says Frost & Sullivan medical analyst Marie Stuckey in the new study, WORLD O
(BW) (UNDER-ONE-ROOF/AIDS) "Give the Gift that Gives Twice" Holiday Catalogue to Raise 200 thousand dollars for AIDS Relief: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Tuesday, 12 November 1996.; SAN FRANCISCO--(BUSINESS WIRE)--Nov. 12, 1996--Under One Roof -- The Shop that benefits the AIDS Community has released its 1996 catalogue of Exclusive Holiday Cards, Gifts and Christmas Ornaments. This unique organization has distributed over three million dollars to AIDS service organizations in the past six years. W
(BW) End-User Study Focuses on Medical Glove Industry: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Tuesday, 12 November 1996.; MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Nov. 12, 1996--Did you know that healthcare workers give the medical glove industry failing grades when it comes to education and increasing awareness of latex sensitivity issues? Or did you know that barrier protection and durability of medical gloves were ranked as the top prio
(BW) EntreMed and National Cancer Institute Expand Thalidomide Clinical Trials: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Tuesday, 12 November 1996.; ROCKVILLE, Md., and BETHESDA, Md.--(HealthWire)--Nov. 12, 1996-- EntreMed Inc. (NASDAQ:ENMD) and the National Cancer Institute (NCI) on Tuesday announced expansion of the number of brain cancer patients currently under observation in NCI-sponsored Phase II clinical trials using thalidomide treatment. The collaborative
(BW) (UNIVERSITY-OF-CALIF-SF) ADVANCE/100 Million Americans Suffer From Chronic Illnesses, According to Estimates from National Study: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Tuesday, 12 November 1996.; (ADVANCE) SAN FRANCISCO--(BUSINESS WIRE)--Nov. 12, 1996--In a study that is likely to focus national attention on a major U.S. health care crisis, researchers have reported that in 1990 approximately 90 million Americans were suffering from chronic illnesses which cost society $659 billion in health expenditures, lost
(BW) BioChem Pharma Lamivudine Appears To Suppress HBV: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; LAVAL, Quebec--(BUSINESS WIRE)--Nov. 10, 1996--Preliminary results were presented today from an ongoing open-label, extended treatment Phase II study in which 24 previously lamivudine-treated, chronically-infected hepatitis B patients were given 100 mg lamivudine, orally, once-daily. Investigators presenting today
(BW) Oklahoma Medical Research Foundation Announces Patents On Procedure To Inactivate HIV In Blood And Blood Products: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Friday, 8 November 1996.; OKLAHOMA CITY--(BUSINESS WIRE)--Nov. 8, 1996--The Oklahoma Medical Research Foundation today announced receipt of patents on an in vitro process for inactivation of the Human Immunodeficiency Virus (HIV) in blood used for transfusions. Testing for HIV and other infectious diseases is required of all potential blood don
(BW) (AIDS-PROJECT-MARCH) "Give Hope a Chance" March against AIDS, Nov. 9: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Thursday, 7 November 1996.; SANTA MONICA, Calif.--(BUSINESS WIRE)--Nov. 7, 1996--With Hope as its theme, a group of Santa Monica AIDS Project clients, volunteers, friends and others will march more than a mile down a major Westside thoroughfare, Saturday, Nov. 9. Dubbed Give Hope a Chance, the march is expected to attract more than 200 people, as
(BW) (NEXSTAR)(NXTR) Independent investigators declare DaunoXome is "active agent" in patients with relapsed or refractory non-Hodgkin's lymphoma: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Thursday, 7 November 1996.; BOULDER, Colo.--(BUSINESS WIRE)--Nov. 7, 1996--NeXstar Pharmaceuticals, Inc., (NASDAQ:NXTR) announced today that a team of independent investigators has presented findings of a phase II study in which DaunoXome ( liposomal daunorubicin citrate for injection) was evaluated as a treatment for low-grade and intermediate-g
(BW) (CONANT-FOUNDATION) The Marcus A Conant Foundation is proud to announce its next Community Forum titled: Management of HIV with VIRACEPT T: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Tuesday, 5 November 1996.; SAN FRANCISCO--(BUSINESS WIRE)--Nov. 5, 1996--VIRACEPT T (nelfinavir mesylate) is a new Protease Inhibitor from Agoroun Pharmaceuticals Inc. scheduled to be released in early 1997. Protease Inhibitors are the latest weapons in the battle against HIV/AIDS. Protease Inhibitors work by interrupting the replication of HIV
(BW) Association of Former Federal Narcotics Agents issues letter to the editor: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Friday, 1 November 1996.; WASHINGTON--(BUSINESS WIRE)--Nov. 1, 1996-- Dear Editor: Election Day is a day when all Americans have the right to exercise their freedom of choice. After much reflection they elect the candidates who they believe will run our nation to the best of their ability, and continue to fight for the ethical and moral values
(BW) IL-2 Therapy Produces Substantial And Sustained Increases In CD4 Counts In People With HIV: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Thursday, 31 October 1996.; EMERYVILLE, Calif.--(BUSINESS WIRE)--Oct. 30, 1996--Chiron Corp. (NASDAQ:CHIR) announced today that infusions of recombinant interleukin-2 ( IL-2 ) in people infected with HIV can produce substantial and sustained increases of CD4 cells, a measure of immune competency, according to a paper published by investigators fr
(BW) NeXstar Pharmaceuticals presents MiKasome data U.S. Food and Drug administration approves IND: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; BOULDER, Colo.--(BUSINESS WIRE)--Oct. 30, 1996--In two presentations made this week, NeXstar Pharmaceuticals (NXTR:NASDAQ) revealed some of the preclinical data included in the Company s recent Investigational New Drug (IND) application for MiKasome. Robert M. Fielding, senior pharmacologist in NeXstar Pharmaceuticals
(BW) (SALIVA-DIAGNOSTIC-SYS)(SALV) Russian military orders Rapid HIV tests from SALV: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; VANCOUVER, Wash.--(BUSINESS WIRE)--Oct. 30, 1996-- Russia , Brazil orders increasing, new orders from SE Asia, Caribbean, Middle East -- Saliva Diagnostic Systems Inc. (SDS) announced Wednesday that the company received orders in October for 60,000 of its rapid, non-laboratory HIV tests from the company s Moscow distri
(BW) (VION-PHARMACEUTICALS)(VION) VION Pharmaceuticals receives patent for new Hepatitis B treatment: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Wednesday, 30 October 1996; NEW HAVEN, Conn.--(HealthWire)--Oct. 30, 1996--VION Pharmaceuticals Inc. (NASDAQ: VION) today announced it has received a patent from the U.S. Patent and Trademark office covering the composition of matter and method of use for treating Hepatitis B virus (HBV) infection with L-2 , 3 -didehydro-dideoxy-5-florocytidine n
(BW) (CYTODYN) FDA Clears Human Testing of New, Nontoxic AIDS Treatment; While Antiviral "Cocktails" Play Offense, New Treatment Would Help Body's Immune System Play Defense: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Tuesday, 29 October 1996.; LOS ANGELES--(BUSINESS WIRE)--Oct. 29, 1996--The U.S. Food and Drug Administration has given CytoDyn clearance to test Cytolin, the first in a new class of nontoxic AIDS drugs. Unlike current AIDS drugs, which attack HIV directly, Cytolin aims to correct the self-destruct mechanism of the immune system that is triggere
(BW) UCSF Study Links Depression to Increased Risk of Death Among HIV Infected Gay and Bisexual Men.: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Sunday, 27 October 1996.; SAN FRANCISCO--(BUSINESS WIRE)--Oct. 27, 1996--Depression increases the risk of death among HIV infected gay and bisexual men, according to a new UCSF study published in the current (Oct. 28) issue of The Archives of Internal Medicine. The UCSF study is the first to measure the effect of chronic depression throughout t
(BW) (HOME-ACCESS) Home Access expands product availability through 1-800-HIV-TEST: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Thursday, 24 October 1996.; HOFFMAN ESTATES, Ill.--(HealthWire)--Oct. 24, 1996--Consumers now have a choice when they call 1-800-HIV-TEST to order an anonymous, home HIV test kit from Home Access Health Corporation. A second, lower cost version of the company s HIV-1 test system is now available for purchase via credit card, check or money order.
(BW) Saliva Hires Regulatory Affairs Director for FDA Campaign: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Wednesday, 23 October 1996.; VANCOUVER, Wash.--(BUSINESS WIRE)--Oct. 23, 1996-- Company intends to file for US approval of rapid HIV tests, says CEO Medical diagnostic developer Saliva Diagnostic Systems Inc. (SDS) has begun a campaign for domestic approval of its rapid, non-laboratory HIV tests by hiring a regulatory affairs director to oversee s
(BW) (HEALTH-PROFESSIONALS)(HPI) Health Professionals Inc.'s Center for Special Immunology subsidiary awarded additional Ryan White funding: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Wednesday, 23 October 1996; FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Oct. 23, 1996--Health Professionals Inc. (ASE:HPI) Wednesday announced that its Center for Special Immunology Inc. (CSI) subsidiary s Fort Lauderdale center has been awarded an additional $50,000 supplement to the $696,391 in Ryan White Care Act funding awarded in September by th
(BW) (CELLPRO)(CPRO) CellPro announces clinical trial for new T-Cell Depletion product: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Monday, 21 October 1996.; SEATTLE--(BUSINESS WIRE)--Oct. 21, 1996--CellPro Inc. (Nasdaq: CPRO) announced today that it has received an Investigational Device Exemption from the U.S. Food and Drug Administration to begin clinical trials with its new product, the CEPRATE(r) TCD T-Cell Depletion System. This device will be used with CellPro s curr
(BW) Gilead Sciences Commences Human Clinical Testing of Systemic PMPA for HIV: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Thursday, 17 October 1996; FOSTER CITY, Calif.--(BUSINESS WIRE)-Oct. 17, 1996-- Gilead Sciences , Inc. (Nasdaq: GILD) announced today the commencement of human clinical studies of PMPA. In preclinical testing, PMPA has demonstrated potent activity against simian immunodeficiency virus (SIV) infection, a primate model for human immunodeficiency v
(BW) (NAMES-PROJECT) AIDS Memorial Quilt in Washington, D.C., draws 1.2 million people over Columbus Day weekend; for first time, U.S. president and vice president visit quilt display: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Thursday, 17 October 1996.; SAN FRANCISCO--(BUSINESS WIRE)--Oct. 17, 1996--An estimated 1.2 million people visited the AIDS Memorial Quilt when it was shown in its entirety in Washington, D.C., over Columbus Day weekend, Oct. 11-13. Stretching from the Washington Monument to the grounds of the U.S. Capitol Building, the Quilt occupied an area equ
(BW) (MEDICAL-DEVICE-TECH)(MEDD)(MEDDP)(MEDDW) Medical Device Technologies Inc.'s study confirms passage of bacteria and viruses through surgical latex gloves: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Thursday, 17 October 1996; SAN DIEGO--(HealthWire)--Oct. 17, 1996--Medical Device Technologies Inc. (NASDAQ:MEDD/MEDDP/MEDDW) Thursday announced that initial results of studies commissioned by the company confirm published data that surgical latex gloves, even in the absence of visible holes or tears, can become permeable to bacteria and viruses
(BW) (UCSF/ANTIVIRAL-DRUG) Antiviral drug more effective than standard cesarean in preventing neonatal herpes, according to UCSF analysis: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Wednesday, 16 October 1996; SAN FRANCISCO--(BUSINESS WIRE)--Oct. 16, 1996--A common antiviral drug taken during the last month of pregnancy is more cost-effective and prevents more neonatal infections than cesarean delivery for women with genital herpes , according to a UCSF analysis published in the current (October) issue of the journal Obstetr
(BW) BioChem Pharma says Emory patent claims invalid: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Tuesday, 15 October 1996.; LAVAL, QUEBEC, Canada--(BUSINESS WIRE)--Oct. 15, 1996--BioChem Pharma filed a response today to a patent infringement suit brought by Emory University. BioChem Pharma is the Canadian-based biopharmaceutical company that discovered Epivir (TM)/ 3TC
(BW) Prop. 211 threatens medical research, study ...: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Tuesday, 15 October 1996; LA JOLLA, CALIF. (Oct. 15) BUSINESS WIRE -Oct. 15, 1996--Proposition 211, unless it is defeated in November, could hinder important advances for 384 new medicines and treatments for disorders like cancer, AIDS, Alzheimer s and heart disease, according to a study released Tuesday by California Healthcare Institute (CHI)
(BW) (CITY-OF-HOPE) City of Hope announces estate and financial- planning forums for professionals: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; LOS ANGELES--(BUSINESS WIRE)--Oct. 15, 1996--The City of Hope National Medical Center and Beckman Research Institute recently announced that it will present a series of estate and financial- planning forums during October for attorneys, accountants and other financial-planning professionals. Titled Estate and Financial
(BW) (GENENTECH)(GNE) Genentech Advances Study of Nerve Growth Factor to Phase III Following Positive Phase II Results; Genentech Gains Revenues as Roche Exercises its Option to Develop NGF Outside U.S.: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Tuesday, 14 October 1996; SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 15, 1996-- Based on promising results of the Phase II trial of Nerve Growth Factor (NGF) in diabetic peripheral neuropathy , Genentech , Inc. (NYSE: GNE) announced today it will advance clinical study of this potential new therapy to late-stage, or Phase III.
(BW) (NORTH-AMERICAN-VACCINE)(NVX) North American Vaccine and Abbott Laboratories Sign Final Agreement on Marketing Alliance for Pediatric Vaccine Product Line: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Tuesday, 15 October 1996; BELTSVILLE, Md. and ABBOTT PARK, Ill.--(BUSINESS WIRE)--Oct. 15, 1996--North American Vaccine (AMEX:NVX) and Abbott Laboratories (NYSE:ABT) today announced that they have signed a definitive agreement for Abbott to market and distribute North American Vaccine s diphtheria, tetanus and acellular pertussis (whooping coug
(BW) Cancer Research Institute Symposium brings news of developing cancer vaccines to New York: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Monday, 14 October 1996; NEW YORK CITY--(BUSINESS WIRE)--Oct. 11, 1996--Defining the molecular structure of antigens recognized by T cells or antibodies has had a profound impact on our thinking and aspirations, began Dr. Lloyd J. Old, introducing Cancer Vaccines 1996, a three-day symposium sponsored by the Cancer Research Institute. Not only
(BW) (NAMES-PROJECT-FDN) ADVISORY/Largest AIDS Awareness Event Ever Begins Tomorrow When AIDS Memorial Quilt is in Washington, D.C.: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Thursday, 10 October 1996; News Editors/City Desks ADVISORY...for Friday-Sunday (Oct. 11-13) --(BUSINESS WIRE)-- 750,000 people will converge on the National Mall when the NAMES Project unfolds all 40,000 panels of the AIDS Memorial Quilt for display October 11, 12 and 13. The theme for opening day is youth and tens of thousands of high school s
(BW) (CELTRIX)(CTRX) Celtrix Receives Third Patent on its Recombinant Protein Production Technology: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Thursday, 10 October 1996; SANTA CLARA, Calif.--(BUSINESS WIRE)--Oct. 10, 1996--The United States Patent and Trademark Office has granted Celtrix Pharmaceuticals, Inc. (Nasdaq: CTRX) U.S. Patent No. 5,563,046 entitled Fusion Polypeptides and Proteins. The new patent relates to Celtrix s recombinant protein production technology for making solubl
(BW) ImmuCell Receives NIH Grant to Commercialize Crypto-Scan Drinking-Water Test: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Wednesday, 9 October 1996; PORTLAND, MAINE--(BUSINESS WIRE)--Oct. 9, 1996--ImmuCell Corp. (NASDAQ:ICCC; BSE:IMU) announced today that the National Institutes of Health (NIH) has awarded the company a $100,000 grant to fund field-testing of Crypto-Scan water diagnostic test and the development of a commercial prototype machine. This NIH grant is
(BW) Medical Discoveries Receives FDA Notice of Allowance for MDI-P Sterilizing Agent as Blood Decontaminant: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Wednesday, 9 October 1996; SALT LAKE CITY--(BUSINESS WIRE)--Oct. 9, 1996--Medical Discoveries Inc. (OTCBB:MLSC) Wednesday announced that the company has received a notice of allowance from the United States Patent and Trademark Office relating to the use of MDI s proprietary MDI-P for the sterilization or inactivation of infectious agents. T
(BW) (HOME-ACCESS-HEALTH) Home Access Health expands nationwide medical and social service referrals for anonymous HIV test service: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Tuesday, 8 October 1996; HOFFMAN ESTATES, Ill.--(HealthWire)--Oct. 8, 1996-- Physicians And Social Service Organizations Encouraged To Apply Home Access Health Corporation announced today that the company is expanding its national listing of more than 13,000 state/local health departments, AIDS service organizations, physicians, and related so
(BW)(NAMES-PROJECT/AIDS-QUILT) Elizabeth Taylor, Maya Angelou, Ram Dass and Patti Smith to Read Names of People Lost to AIDS When AIDS Memorial Quilt is Shown in Washington, D.C., Oct. 11-13; 750,000 people to visit the quilt in largest AIDS awareness event ever: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Monday, 7 October 1996; WASHINGTON--(BUSINESS WIRE)--Oct. 7, 1996--Actress Elizabeth Taylor, writer Maya Angelou, spiritual leader Ram Dass and singer Patti Smith will be among the 2,000 people who will read the names of people lost to AIDS when the entire AIDS Memorial Quilt is displayed in Washington, Oct 11-13. Over the course of the three
(BW) (AIDS-MEMORIAL-GROVE) United States Congress Designates San Francisco's AIDS Memorial Grove as a National Memorial: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Thursday, 3 October 1996; NOTE TO MEDIA: Photo is on Business Wire s photo BBS and Home Page on the World Wide Web. Call 800/221-2462 or 212/752-9600 to receive photo free. SAN FRANCISCO--(BUSINESS WIRE)--Oct. 3, 1996--A historic milestone was reached today with the passage of The AIDS Memorial Grove Act, part of the National Parks Bill, for th
(BW) (HOME-ACCESS/HIV-TEST) 24-hour counseling critical option for anonymous home access HIV testing: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Thursday, 3 October 1996; HOFFMAN ESTATES, Ill.--(HealthWire)--Oct. 3, 1996--Initial data released today by Home Access Health Corporation reinforces the need to offer 24-hour professional counseling for people who use an anonymous Home Access HIV test. This is completely consistent with what we anticipated, noted Jorge Zaysabazan, manager of c
(BW) Cytomegalovirus hides in basic immune cells: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Wednesday, 2 October 1996; STANFORD, CALIF. (Oct. 2) BUSINESS WIRE -Oct. 2, 1996-- A widespread and sometimes deadly virus hides in cells basic to the human immune system, Stanford researchers have discovered. Working with cells from human bone marrow, the scientists identified genes of latent cytomegalovirus (
(BW) UCSF Researchers Develop "Designer Drug" Strategy to Stop the AIDS Virus by Getting HIV to Work Against Itself: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Wednesday, 2 October 1996; SAN FRANCISCO--(BUSINESS WIRE)--Oct. 2, 1996--A new generation of AIDS-fighting drugs could be based on fooling the AIDS virus into using a defective version of one of its own genes, according to a University of California San Francisco scientist. The carefully designed gene would act as a Trojan horse that clinicians
(BW) NeXstar Pharmaceuticals files IND for MiKasome: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Wednesday, 2 October 1996; BOULDER, Colo.--(BUSINESS WIRE)--Oct. 2, 1996--NeXstar Pharmaceuticals, Inc. (NASDAQ:NXTR) announced today that it has filed an Investigational New Drug application (IND) with the U.S. Food and Drug Administration ( FDA ) for clinical testing of MiKasome in patients with a variety of serious bacterial and mycobacterial
(BW) Home Access HIV Test Available At Reduced Rate To Nonprofit Organizations; Anonymous HIV Test Option To Boost Public Health Efforts In Reaching People At Increased Risk For HIV: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Monday, 30 September 1996; HOFFMAN ESTATES, Ill.--(HealthWire)--Sept. 30, 1996--In support of National AIDS Awareness Month, Home Access Health Corporation announced today that beginning October 1, nonprofit organizations will be able to purchase the company s Home Access(TM) HIV-1 Test System at reduced cost to help make anonymous HIV testing a
(BW) Hoffmann-La Roche, Gilead Sciences Announce Collaboration To Co-promote Potential Hepatitis C Treatment In The U.S.: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; NUTLEY, N.J. and FOSTER CITY, Calif.--(HealthWire)-- Sept. 30, 1996-- Hoffmann-La Roche Inc. and Gilead Sciences , Inc. (Nasdaq: GILD) announced today that they have entered into a collaboration to co-promote Roche s Roferon(R)-A (Interferon alfa-2a, recombinant) for the potential treatment of chronic
(BW) (WA-STATE-DEPT-OF-HEALTH) It's time to get your flu shot: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; OLYMPIA, Wash.--(BUSINESS WIRE)--Sept. 30, 1996--Flu season is fast approaching. This year, the state Department of Health recommends that persons who want to protect themselves from flu get their influenza immunizations between Oct. 1 and mid-November. For the last two years, flu season has come early in Washington,
(BW) (ANIMAL-PROTECTION-INST) Xenotransplantation Guidelines Labeled "Financially Irresponsible, Morally Indefensible, A Grave Public Health Danger" by Alan Berger of Animal Protection Institute: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; SACRAMENTO, Calif.--(BUSINESS WIRE)--Sept. 26, 1996-- Financially irresponsible, morally indefensible, and a grave public health danger is how Alan Berger, executive director of the Animal Protection Institute, characterized the proposed new guidelines for xenotransplantation -- the transplantation of animal organs int
(BW) Boston Probes begins operations; Will develop diagnostics using unique technology: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; BEDFORD, Mass.--(BUSINESS WIRE)--Sept. 26, 1996--Boston Probes Inc. (BPI) announced today that it has commenced operations at its facility in Bedford, Mass. The company is developing diagnostic tests using its licensed PNA (peptide nucleic acid) technology. Organisms have unique DNA and RNA sequences or fingerprints. W
(BW) (HOME-ACCESS-HEALTH) Home Access HIV-1 Test System available at Eckerd Drugstores: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; HOFFMAN ESTATES, Ill.--(HealthWire)--Sept. 24, 1996--A new major drug store chain is now selling Home Access Health Corporation s Home Access Express(TM) HIV-1 Test System over-the-counter, the company announced. Home Access Express(TM) is available at more than 1,700 Eckerd drug stores in 13 states across the country.
(BW) VIMRx Elaborates on Clinical Trial Results for AIDS; Results Met Objective of Identifying a Well-Tolerated Oral Dose for Future Research: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; WILMINGTON, Del.--(BUSINESS WIRE)--Sept. 23, 1996--In response to investor inquiries, VIMRx Pharmaceuticals Inc. (Nasdaq SmallCap:VMRX) has stated that the Phase I/Phase II clinical trial results announced on September 19, 1996, met the objective of the trial, which was to identify a well-tolerated oral dose for use in
(BW) MWD's Water-quality Laboratory Expands For 21st Century Challenges: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; LOS ANGELES--(BUSINESS WIRE)--Sept. 20, 1996--In a precast concrete building about a mile outside of downtown La Verne, 90 men and women work to ensure that Southern California s tap water looks good, smells good, tastes good and is safe to drink. It s a demanding task, performed in a building built to accommodate abou
(BW) Genta Reports Biological Activity Of G3139 Antisense Compound In Various Types Of Cancer: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; SAN DIEGO--(BUSINESS WIRE)--Sept. 20, 1996--Genta Inc. (NASDAQ:GNTA) Friday presented preclinical and interim clinical trial results showing biological activity of its lead antisense compound, G3139, against several cancer types at the 12th International Roundtable on Nucleosides, Nucleotides and Their Biological Appli
(BW) VIMRx Reports Clinical Trial Results For VIMRxyn for AIDS: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; WILMINGTON, Del.--(BUSINESS WIRE)--September 19, 1996--VIMRx Pharmaceuticals Inc. (Nasdaq SmallCap:VMRX) has announced that results from its Phase I/Phase II clinical trial in Thailand indicate that a well tolerated oral dose with no untoward toxicity or cutaneous photosensitivity has been identified as 0.05 mg/kg of V
(BW) Clinical Data For Sequus Pharmaceuticals' AMPHOTEC Product Indicate Safety And Efficacy In Treatment Of Refractory Patients With Systemic Candida Fungal Infections: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; NEW ORLEANS--(BUSINESS WIRE)--Sept. 19, 1996--Data from five open label trials of AMPHOTEC(TM) in the treatment of invasive fungal infection, reviewed today at the 34th Annual Meeting of the Infectious Diseases Society of America by Dr. Gary Noskin of Northwestern Memorial Hospital and Northwestern University Medical S
(BW) NeXstar Pharmaceuticals makes announcement: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; NEW ORLEANS, La.--(BUSINESS WIRE)--Sept. 17, 1996--Independent European investigators today will present data from two multi-center, phase III comparative clinical trials conducted with AmBisome, NeXstar Pharmaceuticals liposomal formulation of amphotericin B. The presentations will be made this afternoon in New Orlean
(BW) Health Professionals Inc.'s Center for Special Immunology subsidiary awarded $696,391 in Ryan White funding: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Sept. 19, 1996--Health Professionals Inc. (ASE:HPI) Thursday announced that its Center for Special Immunology Inc. (CSI) subsidiary s Fort Lauderdale center has been awarded $696,391 in Ryan White Care Act funding by the Broward County Commission. The funds will be used to provid
(BW) XOMA ICAAC Presence Focused On BPI-Derived Fungicidal Peptides and Extended Bactericidal Spectrum for Neuprex: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; BERKELEY, Calif.--(BUSINESS WIRE)--Sept. 16, 1996-- XOMA Corporation (Nasdaq: XOMA) scientists will present new research developments in five presentations Tuesday September 17th at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), an annual meeting of the American Society for Microbiol
(BW) Chiron Renames Chiron Biocine Chiron Vaccines: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; EMERYVILLE, Calif.--(BUSINESS WIRE)--Sept. 16, 1996--Chiron Corp. (NASDAQ: CHIR) announced today that it has formally changed the name of the company s 10-year-old vaccine business unit from Chiron Biocine to Chiron Vaccines. Chiron is launching the new name during the 36th annual Interscience Conference on Antimicrobi
(BW) Gilead Sciences Announces Statistically Significant Antiviral Activity Against Hepatitis B Virus; GS 840 Data from Phase I/II Human Clinical Study to be Presented Today at 36th ICAAC Conference: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; FOSTER CITY, Calif.--(HealthWire)--Sept. 16, 1996-- Gilead Sciences , Inc. (Nasdaq: GILD) announced today Phase I/II data demonstrating that during treatment, GS 840 (adefovir dipivoxil) was well tolerated and resulted in significant and sustained antiviral activity against
(BW) Popularity of DHEA hormone could rival melatonin: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; MARINA DEL REY, Calif.--(BUSINESS WIRE)--Sept. 12, 1996--The popularity of an over-the-counter hormone is about to skyrocket, said Ray Sahelian, M.D., author of newly published DHEA: A Practical Guide (Avery Publishing Group, $9.95). For the last few months DHEA, a hormone made by the adrenal glands, has been available
(BW) EPA Makes Possible Agreement To Protect NYC's Drinking Water: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; NEW YORK--(BUSINESS WIRE)--Sept. 10, 1996--U.S. Environmental Protection Agency (EPA) Administrator Carol Browner announced that the Agency intends to issue a determination allowing New York City to protect the quality of its drinking water by preventing pollution at the source in the upstate watershed. Browner reveale
(BW) (PROCEPT)(PRCT) Procept to develop gel to prevent sexual transmission of HIV in women; Key preclinical results presented at AIDS conference: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 10, 1996-- Procept Inc. (NASDAQ: PRCT) announced today plans to develop a topical microbicide women can use vaginally to help prevent HIV infection and other sexually transmitted diseases (STDs). Procept believes its PRO 2000 antiviral compound is well suited for development as
(BW) Russia okays Saliva Diagnostic's fast HIV test; Trial Results 100%, Test Has "Indisputable Advantages" Per Russian Commission: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; VANCOUVER, Wash.--(BUSINESS WIRE)--Sept. 9, 1996--The Russian Ministry of Health has approved Hema Strip HIV-1/2, a rapid, non-laboratory HIV test developed by Saliva Diagnostic Systems Inc. (SDS), for use and sale in Russia, said SDS President Ronald Lealos on Monday. Sensitivity and specificity results for the whole
(BW) GumTech to Make and Market DHEA Gum for Body Ammo; Company Sees Excellent Opportunity for its Innovative Delivery-system Technology: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; PHOENIX--(BUSINESS WIRE)--Sept. 6, 1996--GumTech International Inc. (NASDAQ:GUMM) Friday announced it will manufacture, sell and distribute a chewing-gum product containing the hormone DHEA, to be marketed under the Body Ammo brand. Body Ammo is a leader in DHEA products nationwide. GumTech will also sell and distribut
(BW) Theratech And Astra Receive Clearance To Market Testosterone Patch In Denmark: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; SALT LAKE CITY and SODERTALJE, Sweden--(BUSINESS WIRE)-- Sept. 5, 1996--TheraTech Inc. (NASDAQ:THRT) and Astra AB Thursday announced that ATMOS(R), their testosterone transdermal patch, has been granted marketing approval in Denmark by the Danish National Board of Health. This represents the second approval for ATM
(BW) Survey shows Hepatitis A is misunderstood, media play key education role: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; WEST POINT, Pa.--(BUSINESS WIRE)--Sept. 5, 1996--Even in areas where hepatitis A is common, Americans tend to underestimate its risks, according to a recent Gallup survey. The survey was commissioned by Merck & Co. , Inc. which recently received approval from the Food and Drug Administration (
(BW) France Approves NeXstar Pharmaceuticals' DuanoXome: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; BOULDER, Colo.--(BUSINESS WIRE)--Sept. 4, 1996--NeXstar Pharmaceuticals Inc. (NASDAQ:NXTR) announced today that the French Ministry of Health has approved DaunoXome as primary therapy for advanced AIDS related Kaposi s sarcoma in severely immuno-compromised patients with extensive involvement of the skin, mucous membra
(BW) (THERATECH/MASS-GNRL-HOSP)(THRT) Boston study to evaluate new testosterone patch for treatment of women with AIDS wasting syndrome: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; BOSTON--(BUSINESS WIRE)--Sept. 4, 1996--The Massachusetts General Hospital, a teaching hospital of the Harvard Medical School, and TheraTech Inc. (NASDAQ:THRT), Salt Lake City, Wednesday announced initiation of a pilot study to assess a new approach for treating women with the AIDS wasting syndrome. The treatment uses
(BW) Nationwide HIV Home Test Maker Launches Web Site: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; HOFFMAN ESTATES, Ill.--(HealthWire)--Aug. 30, 1996--Home Access Health Corporation, maker of the Home Access(TM) and Home Access Express(TM) HIV-1 test systems, has gone on-line with its new Internet site on the world wide web. Web surfers can hook up with the Home Access web site at either www.homeaccess.com or www.80
(BW) DHEA: Melatonin's Younger Sibling: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; (BUSINESS WIRE FEATURES)--Shortly after all the media attention on melatonin (the sleep inducing, anti-aging, over-the-counter supplement) we are now hearing a buzz on the supplement called DHEA. People are claiming that DHEA can: increase your energy level, enhance sex drive, decrease body fat, reduce stress and reduc
(BW) Home Access HIV-1 Test Systems available at Rite Aid drugstores: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; HOFFMAN ESTATES, Ill.--(HealthWire)--Aug. 28, 1996--Home Access Express(TM) and Home Access(TM) HIV-1 Test Systems are now available at Rite Aid drugstores in several states across the country. The Home Access Test Systems allow people to anonymously collect a blood sample, access professional pre-test and post-test co
(BW) (ALFACELL/ONCONASE)(ACEL) Novel RNase cancer drug shows promise for AIDS; ONCONASE inhibits the HIV virus: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; BLOOMFIELD, N.J.--(BUSINESS WIRE)--Aug. 26, 1996--In vitro findings published in the Aug. 23 issue of Journal of Biological Chemistry (Vol. 271:2073-20788) revealed that ONCONASE(R), a novel anticancer ribonuclease, significantly inhibited production of the human immunodeficiency virus (HIV-1) in several persistently i
(BW) (KAISER-PERMANENTE) HMO web site offers health tips in 90 subject areas, class information, research results and more: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; PASADENA, Calif.--(BUSINESS WIRE)--Aug. 21, 1996--Most people get their information on health care subjects from either their doctors or the media. But now, they can also get interesting and useful health-related information by visiting the Kaiser Permanente California World Wide Web site at (http://www.KaiserPermanent
(BW) (CYTEL-CORP)(CYTL) Cytel awarded grant to develop Theradigm technology for testing in a primate model of AIDS: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; SAN DIEGO--(BUSINESS WIRE)--Aug. 21, 1996--Cytel Corporation (NASDAQ:CYTL) announced today that it has been awarded a Phase I Small Business Innovation Research Program (SBIR) grant from the National Institutes of Health (NIH) through the National Institute of Allergy and Infectious Diseases (NIAID). In collaboration w
(BW) TheraTech And Astra Announce Second European Launch Of Testosterone Patch: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; SALT LAKE CITY and SODERTALJE, Sweden--(BUSINESS WIRE)-- Aug. 14, 1996--TheraTech Inc. (NASDAQ:THRT) and Astra AB Wednesday announced that Astra has begun marketing the Atmos(R) testosterone transdermal patch in Sweden. Atmos, which was developed by TheraTech, is intended for the treatment of male hypogonadism, a syndr
(BW) E. Coli, Cryptosporidium Barrier Earns U.S. Patent For Sionix Corp.: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; SAN DIEGO--(BUSINESS WIRE)--Aug. 14, 1996-- This filter technology is a major breakthrough in America s efforts to purify our drinking water, declared Jack Moorehead, president of Sionix Corp. (NASDAQ:SINX), in announcing that the company has been awarded a U.S. patent for an essential component of its modular filtrati
(BW) (SEQUUS-PHARMACEUTICALS)(SEQU) Clinical Data Indicate That DOXIL is Useful for Treating Patients with Advanced Kaposi's Sarcoma: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; MENLO PARK, Calif.--(BUSINESS WIRE)--Aug. 12, 1996--SEQUUS Pharmaceuticals, Inc. (Nasdaq:SEQU) today reported results from a randomized clinical trial comparing DOXIL with combination bleomycin and vincristine (BV) therapy in treating Kaposi s sarcoma (KS) in people with AIDS. These data, which were presented at the
(BW) VIMRx Gets Approval To Begin Phase I Cancer Trial; Multi-Faceted Vimrxyn Drug Now In Clinicals For Cancer And AIDS: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; STAMFORD, Conn.--(BUSINESS WIRE)--Aug. 8, 1996--VIMRx Pharmaceuticals Inc. (Nasdaq SmallCap: VMRX) announced today that it has received approval from the Institutional Review Board of the University of North Dakota of its clinical protocol to study VIMRxyn to treat recurrent malignant gliomas in brain cancer patients.
(BW) BioChem Pharma Inc. - Epivir(TM)(3tc(R)) Approved In The European Union: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; LAVAL, Quebec--(BUSINESS WIRE)--Aug. 8, 1996--BIOCHEM PHARMA INC.(TSE, ME: BCH NASDAQ: BCHXF ) BioChem Pharma Inc. announced today that the European Medicines Evaluation Agency (EMEA) has approved the application, made by Glaxo Wellcome plc, to market the anti-HIV drug
(BW) Sequus Pharmaceuticals Signs Marketing Agreement For AMPHOTEC In Austria And Eastern Europe With TORREX: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; MENLO PARK, Calif.--(BUSINESS WIRE)--Aug. 7, 1996--SEQUUS Pharmaceuticals, Inc. (NASDAQ:SEQU) today announced the signing of an exclusive agreement with TORREX Pharma Ges. m. b. H. of Vienna, Austria for the marketing and distribution of AMPHOTEC(TM) in Austria, the Czech Republic ,
(BW) (CALYPTE-BIOMEDICAL)(CALY) First urine test for HIV-1 antibodies licensed by U.S. Food and Drug Administration: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; WASHINGTON--(BUSINESS WIRE)--Aug. 6, 1996--Calypte Biomedical Corp., a Berkeley, Calif.-based diagnostic research and development company Tuesday received notification from the FDA of the licensure of its diagnostic test for the detection of antibodies to HIV-1 in urine. We are extremely pleased that years of research
(BW) Metropolitan Hails Signing Of 1996 Safe Drinking Water Act: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; LOS ANGELES--(BUSINESS WIRE)--Aug. 6, 1996--President Bill Clinton s signing Tuesday of the revised law governing the nation s drinking water was hailed by Metropolitan Water District as crucial in improving public health protection. By signing this legislation, President Clinton has triggered the most significant enha
(BW) First Urine Test For HIV-1 Antibodies Licensed By U.S. Food And Drug Administration: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; WASHINGTON--(BUSINESS WIRE)--Aug. 6, 1996--Calypte Biomedical Corp., a Berkeley, Calif.-based diagnostic research and development company Tuesday received notification from the FDA of the licensure of its diagnostic test for the detection of antibodies to HIV-1 in urine. We are extremely pleased that years of research
(BW) Sequus Pharmaceuticals Signs Marketing Agreement For Amphotec In Spain, Belgium And Luxembourg With Prodesfarma: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; MENLO PARK, Calif.--(BUSINESS WIRE)--Aug. 6, 1996--SEQUUS Pharmaceuticals, Inc. (Nasdaq:SEQU) today announced the signing of an exclusive agreement with Prodesfarma, S.A. for the marketing and distribution of AMPHOTEC in Spain , Belgium and Luxembourg .
(BW) NeXstar Pharmaceuticals, Roche Molecular Systems Sign Research And Development Agreements For Aptamer-Based PCR Application: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; BOULDER, Colo.--(BUSINESS WIRE)--Aug. 2, 1996--NeXstar Pharmaceuticals, Inc. (NASDAQ:NXTR) and Roche Molecular Systems, Inc. (RMS) announced today that RMS has signed a research and development agreement involving one application of NeXstar Pharmaceuticals SELEX Combinatorial Chemistry Process. This collaboration calls
(BW) Nearly $5 Million Needed To Fully Fund HIV/AIDS Prescription Drug Program: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; OLYMPIA, Wash.--(BUSINESS WIRE)--Aug. 2, 1996--Gov. Mike Lowry presented to the Senate Health and Long-Term Care Committee today the reasons why close to $5 million will be needed to meet the anticipated needs of the HIV/AIDS prescription drug program. Gov. Lowry said if the program continues to accept unlimited enroll
(BW) (UCSF/CAT-SCRATCH) Fleas Infect Cats with Organism that Causes "Cat Scratch Disease" in Humans, Say University of California Researchers: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; SAN FRANCISCO--(BUSINESS WIRE)--Aug. 1, 1996--An organism that causes a rare bacterial disease in some people who are scratched by infected cats is transmitted between felines by the common cat flea, according to new study results by researchers at the University of California San Francisco and at UC Davis. The finding
(BW) (JOHNSON-&-JOHNSN-MEDICAL) Johnson & Johnson Medical announces safety I.V. catheter milestone; Highlights improved health care worker safety from HIV and other bloodborne threats: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; ARLINGTON, Texas--(HealthWire)--July 31, 1996--Since the company s inception, protecting health care professionals and patients alike has been at the forefront of the Johnson & Johnson Medical Inc. mission. This month, the company s Vascular Access Business Unit announced production of the 100 millionth PROTECTIV(T
(BW) UCSF Research Links A Sexually Transmitted Virus To Cancer Development In AIDS Patients: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; SAN FRANCISCO--(BUSINESS WIRE)--July 30, 1996--A new test developed by researchers at the University of California San Francisco strongly implicates a sexually transmitted virus in the development of Kaposi s sarcoma, the most common cancer of AIDS patients. The results, which are presented in the August issue of Natur
(BW) (INTL-CONFERENCE-ON-AIDS) Survey finds AIDS -- like diabetes -- can be managed: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; Health/Medical Editors Physicians say monthly monitoring may help manage AIDS, control progression of the disease. But what s the protocol? Doctors discuss options CHICAGO--(HealthWire)--July 29, 1996--Living decades with AIDS? Managing the disease like diabetes? These ideas would seem far-fetched just months ago, but
(BW) (HOME-ACCESS-HIV-PHOTO) ADVISORY/Medical photo of Home Access HIV-1 home testing and counseling system from Home Access Health Corp. is available on Business Wire's Photo Bulletin Board (BBS): BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; Photo & Health/Medical Editors ADVISORY... NOTE TO MEDIA: Photo is on Business Wire s Photo Bulletin Board Service (BBS). Call 800/221-2462 or 212/752-9600 to receive a user ID and password to download photos at no cost from Business Wire s BBS. --(BUSINESS WIRE)-- Photo caption reads: Home Access Express(TM) is th
(BW) BioChem Pharma Inc. - Epivir 3TC Clinical Endpoint Study Stopped Early Results Show Significant Reduction In HIV Disease Progression Or Death: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; LAVAL, Quebec--(BUSINESS WIRE)--July 23, 1996-- BioChem Pharma Inc. today announced that a study to determine the effect of the anti-HIV therapy 3TC (R) ( Epivir (TM)) on survival or delay in disease progression has been stopped after an interim analysis of data showed
(BW) Allelix - Canadian Scientists Discover Role Of Intestinal Growth Hormone New Treatments Now Made Possible For Debilitating Bowel Diseases: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; TORONTO--(BUSINESS WIRE)--July 23, 1996--ALLELIX BIOPHARMACEUT (TSE, ME:AXB) Canadian scientists announced today the discovery of the function of the peptide-hormone GLP-2, a finding that will likely lead to treatments that will help thousands of people who suffer from intestinal diseases that interfere with the body s
(BW) Sequus Announces Receipt Of 20-Month Shelf Life Approval For Doxil From U.S. Food And Drug Administration: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; MENLO PARK, Calif.--(BUSINESS WIRE)--July 23, 1996--SEQUUS Pharmaceuticals, Inc. (Nasdaq: SEQU) today announced that the United States Food and Drug Administration has approved a change in the expiration date of DOXIL , increasing shelf life to 20 months. DOXIL(R) (doxorubicin HCl liposome injection) is the Company
(BW) (THE-NAMES-PROJECT) President Clinton and the First Lady To Serve as Honorary Co-Chairs For the Display of the Entire AIDS Memorial Quilt This Fall: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; SAN FRANCISCO--(BUSINESS WIRE)--July 22, 1996--President Bill Clinton and First Lady Hillary Rodham Clinton have agreed to serve as Co-Chairs of the Honorary Host Committee for the display of the entire AIDS Memorial Quilt in Washington, D.C., which will occur Oct. 11-13, 1996. This is the first time a U.S. president h
(BW) Arbitrator Hands Down Ruling In Favor Of Former Johnson & Johnson Executive Seeking Return Of Assets Of HIV Testing Company He Sold To J&J: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; NEWARK, N.J.--(BUSINESS WIRE)--July 16, 1996--An arbitrator has handed down a ruling in favor of a former Johnson & Johnson executive in a case in which the executive is seeking the return of all of the assets of the HIV testing company he sold to Johnson & Johnson in 1993. In a ruling handed down yesterday,
(BW) Pace Launches HIV Test: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; TORONTO--(BUSINESS WIRE)--July 16, 1996--THE PACE CORPORATION(CANADIAN DEALING NETWORK:PACL) The Pace Corporation today announced that it has acquired rights to market and distribute an easy to use and rapid diagnostic test to detect the presence of HIV antibodies that are associated with AIDS. The initial release of t
(BW) Updated Report On State Water Project Efforts To Assure Water Quality: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; SACRAMENTO, Calif.--(BUSINESS WIRE)--July 16, 1996--The Department of Water Resources (DWR) and the State Water Contractors today announced publication of a new report on the Department s efforts to assure high-quality drinking water. The report is entitled California State Water Project Sanitary Survey Update Report-1
(BW) For Some Children With HIV, Early Treatment Doesn't Prolong Life: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; PALO ALTO, Calif.--(BUSINESS WIRE)--July 11, 1996-- Starting standard drug treatments before symptoms appear fails to extend the lives of HIV-infected children who progress quickly to AIDS, a Stanford researcher reports. Researchers have found that children with HIV, like their adult counterparts, fall into two groups.
(BW) International Panel Says: Treat HIV Early, Often: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; PALO ALTO, Calif.--(BUSINESS WIRE)--July 10, 1996-- Treat HIV infection early and often will be the primary message of a July 10 symposium on managing HIV, said Dr. David Katzenstein, an assistant professor of medicine at Stanford, who is part of an international panel working on new guidelines for the use of antiretro
(BW) AZT Has Another Trick Up Its Sleeve: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; PALO ALTO, Calif.--(BUSINESS WIRE)--July 11, 1996--With the help of a new assay, researchers have found a second way in which the drug AZT fights HIV infection. In addition to attacking the virus directly, AZT appears to help the immune system attack it. The new assay -- a lab procedure that distinguishes different
(BW) Teens Want To Talk To Parents About AIDS And Sexual Risk-Taking But Find It Difficult, According To UCSF Study: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; (ADVANCE) VANCOUVER, Canada--(BUSINESS WIRE)--July 11, 1996-- Many adolescents want to talk to their parents about HIV infection and taking sexual risks but find it difficult to communicate on these sensitive topics, according to a University of California San Francisco study presented at the 11th International Confere
(BW) BioChem Pharma Inc. Triple Combination Of 3TC/AZT With Protease Inhibitor Reduces HIV To Undetectable Levels: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; MONTREAL--(BUSINESS WIRE)--July 11, 1996--BIOCHEM PHARMA INC.(TSE, ME: BCH NASDAQ: BCHXF ) BioChem Pharma Inc. today announced that the latest data, to be presented in three separate sessions today at the XI International Conference on AIDS in Vancouver, British Columbia, consistently show that co
(BW) CDI Orders Unlicensed Viatical To Cease Calif. Sales; Texas-Based Life Partners Illegally Marketed Viatical Settlements To The Terminally Ill, Department Charges: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; SAN FRANCISCO--(BUSINESS WIRE)--July 11, 1996--A Texas-based viatical-settlement company has been ordered to cease marketing in California after a Department of Insurance investigation found that it had been illegally conducting business in the state without proper licensing. Issued this week, the cease-and-desist orde
(BW) (UCSF/HIV-STUDY) ADVANCE/UCSF Study Finds 1-2 Percent Of Young Gay And Bisexual Men In San Francisco Continue To Become HIV Infected: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; (ADVANCE) VANCOUVER, British Columbia--(BUSINESS WIRE)--July 11, 1996--Between one and two percent of young gay and bisexual men who live in San Francisco are continuing to become newly infected with the AIDS virus each year, according to a University of California San Francisco study that was presented at the 11th Int
(BW) PDT Inc. And UCSF Present Photodynamic-Therapy KS Data At World AIDS Conference: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; SANTA BARBARA, Calif.--(BUSINESS WIRE)--July 11, 1996--PDT Inc. and Roy C. Grekin, M.D., chief, dermatology surgery, University of California, San Francisco (UCSF), Wednesday are presenting UCSF s results from Phase I/II clinical trials using PDTI s investigational photodynamic drug SnET2 for AIDS-associated Kaposi s s
(BW) Health Professionals Inc. Announces AIDS Research Collaboration: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--July 10, 1996--Health Professionals Inc. (ASE:HPI) Wednesday announced that its Center for Special Immunology Inc. (CSI) subsidiary and ImmuCell Corp. (NASDAQ:ICCC,BSE:IMU) have agreed to initiate a phase II efficacy study of ImmuCell s drug CryptoGAM(tm) bovine anti-Cryptosporid
(BW) Patients With HIV-Associated Wasting Lose Similar Proportions Of Fat And Lean, UCSF Study Finds: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; VANCOUVER, British Columbia--July 10, 1996--It has long been thought that patients who suffer HIV-associated wasting lose most of their weight in valuable lean tissue while preserving fat. But that idea is challenged in two new studies by a University of California San Francisco research team. The UCSF researchers foun
(BW) (UCSF-2) ADVANCE/Latino Gender Role Beliefs Impede Condom Use, According to UCSF Researchers: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; (ADVANCE) VANCOUVER, British Columbia--(BUSINESS WIRE)-- July 10, 1996--Latino men and women who have more conservative and traditional gender role beliefs are less likely to use condoms and must be specifically targeted by HIV prevention programs, according to UCSF researchers who presented study findings at the 11th
(BW) European Phase II/III pivotal 3TC/AZT data: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; MONTREAL (July 10) BUSINESS WIRE -July 10, 1996--BioChem Pharma Inc. announced today that the two pivotal European Phase II/III studies conducted in AZT-experienced and AZT-therapy naive patients evaluating the effect of 3TC (R) in combination with AZT on surrogate markers of HIV were published in this week s July 10,
(BW) ADVANCE/An Early Blast of AZT Helps, Pilot Study ...: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; PALO ALTO, CALIF. (July 10) BUSINESS WIRE -July 10, 1996-- AZT treatment begun during the first few weeks of HIV infection results in improvement in immune cell levels and may provide long-term benefits after therapy is stopped. People are still sitting on the fence on this issue: Should we or should we not give drugs
(BW) ADVANCE/UCSF Team Identifies Immune Responses That ...: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; (ADVANCE) VANCOUVER, BRITISH COLUMBIA (July 10) BUSINESS WIRE -July 10, 1996--Many long-term partners of persons infected with HIV, the AIDS virus, who remain HIV-negative -- despite practicing unsafe sex -- exhibit distinctive immune-system responses that may help prevent infection, according to a leading AIDS researc
(BW) ADVANCE/Rates of HIV in Vietnam are Rapidly Increasing: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; VANCOUVER, BRITISH COLUMBIA (July 10) BUSINESS WIRE -July 10, 1996--Increasing rates of HIV infection among injecting drug users and commercial sex workers in Ho Chi Minh City, Vietnam , call for urgent prevention efforts, including treatment and control of other sexually transmitted diseases, said a UCSF international
(BW) AIDS Patients On Growth Hormone Gain Weight Without Eating More, UCSF Study Finds: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; VANCOUVER, Canada--(BUSINESS WIRE)--July 8, 1996--Patients with HIV-associated wasting who received daily injections of human growth hormone gained weight, particularly lean body mass, without consuming significantly more calories, according to the results of a University of California San Francisco study presented her
(BW) Societal Factors Lead To Spread Of HIV, According To UCSF Researcher: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; VANCOUVER, British Columbia--(BUSINESS WIRE)--July 6, 1996-- Society s failure to deal with drug problems in a rational way and to recognize that adolescents are sexual are factors that lead to the spread of HIV, according to a UCSF researcher who participated in a satellite symposium on HIV prevention today (July 6),
(BW) European phase II data show DaunoXome produces 73: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; BOULDER, COLO. (July 1) BUSINESS WIRE -July 1, 1996--NeXstar Pharmaceuticals, Inc., (NASDAQ:NXTR) announced today the publication of the results of European phase II studies in which DaunoXome ( liposomal daunorubicin citrate for injection) was assessed as a treatment for advanced AIDS-associated Kaposi s sarcoma.
(BW) Cyclospora Spotlight Shifts Away From Strawberries: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; SAN FRANCISCO--(BUSINESS WIRE)--June 27, 1996--Nearly two weeks after setting off a panic by blaming strawberries for an outbreak of a stomach-churning parasite, the Texas Department of Health late Thursday change direction and lifted its caution against strawberries. The Centers for Disease Control also released a rep
(BW) Accelerated Aging of Immune Cells Linked to: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; MENLO PARK, CALIF. (June 27) BUSINESS WIRE -June 27, 1996--Research focused on a key marker of cell replication demonstrates that the immune cells of HIV-infected patients age at an accelerated rate, suggesting an explanation for the eventual breakdown of the immune response in AIDS. The findings, published today in th
(BW) California takes HIV testing seriously: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; LOS ANGELES (June 27) BUSINESS WIRE -June 25, 1996-- National HIV Testing Day is a day devoted to encouraging people to get an HIV test. If you think you ve put yourself at risk -- it s time to get tested for HIV. Who Is Making It Happen in California? The California Department of Health Services Office of AIDS launche
(BW) FDA Grants Marketing Clearance of Gilead's VISTIDE(R): BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; FOSTER CITY, CALIF. (June 27) HEALTHWIRE -June 27, 1996-- Gilead Sciences Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration ( FDA ) granted marketing clearance of VISTIDE(R) ( cidofovir injection) for the treatment of
(BW) Part 3 Of 3; Cyclospora: A Recently Discovered Parasite; Dr. Charles Sterling, Department Of Veterinary Science, University Of Arizona: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; TUCSON--(BUSINESS WIRE)--June 21, 1996--Overview Public health officials are seeking the cause of a recent outbreak of Cyclospora Cayetamensis, a protozoan parasite. The microbe can cause cramping abdominal pain, severe diarrhea, nausea, fever and extreme fatigue; it is treatable with antibiotics sold as Bactrim or Sep
(BW) AmBisome And Daunoxome Gain Additional Approvals: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; BOULDER, Colo.--(BUSINESS WIRE)--June 17, 1996--NeXstar Pharmaceuticals, Inc. (NASDAQ:NXTR) announced today that Norway has granted final marketing authorization for DaunoXome as a primary therapy for advanced AIDS-related Kaposi s sarcoma. Fifteen countries have approved DaunoXome as primary therapy for advanced AIDS-
(BW) Therapeutic Peptide Products To Double In Number By 1999: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; MOUNTAIM VIEW, Calif.--(BUSINESS WIRE)--Therapeutic peptides are becoming more important in treating conditions such as prostate cancer, endometriosis, and acromegaly. According to the medical market research firm, Frost & Sullivan, U.S. MARKET FOR SYNTHETICALLY DERIVED THERAPEUTIC PEPTIDES, the number of peptide p
(BW) Kenosha Water Treatment Plant: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; WINDSOR, Australia--(BUSINESS WIRE)--June 17, 1996--Memcor has just received an $8.3 million purchase order for Continuous Microfiltration (CMF) equipment to be supplied to the Kenosha water Utility in Kenosha, Wis., USA. This water treatment plant, when commissioned in 1998, will be the largest microfiltration plant f
(BW) Tips on avoiding cyclospora related illness: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; NEW YORK (June 14) BUSINESS WIRE -June 14, 1996--A small outbreak of a digestive illness caused by cyclospora, a parasite that city health officials believe may be harbored in strawberries shipped in from California, has resulted in at least 26 cases of illness in New Yorkers this week. John Asher, M.D., medical direct
(BW) AIDS Memorial Quilt Archive Project Granted ...: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; SAN FRANCISCO (June 12) BUSINESS WIRE -June 12, 1996--The NAMES Project Foundation s AIDS Memorial Quilt Archive Project has received a grant of $100,000 from the National Endowment for the Arts (NEA) to help photograph and document the AIDS Memorial Quilt, the world s largest community arts project and the most recogn
(BW) Potential Cryptosporidium Detection Breakthrough Subject Of Metropolitan Water District Patent Application: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; LOS ANGELES--(BUSINESS WIRE)--June 11, 1996--A potential breakthrough in quicker and improved detection of the notorious Cryptosporidium pathogen in public drinking water is the subject of a U.S. patent application by the Metropolitan Water District of Southern California. This new process for detecting Cryptosporidium
(BW) Enrollment Of HIV-Infected Patients Initiated In Nationwide Low Dose Oral Alpha Interferon Study: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; NEW BRUNSWICK, N.J.--(HealthWire)--June 6, 1996--Interferon Sciences, Inc. (NASDAQ:IFSC) announced today it is participating in a randomized, placebo-controlled, multicenter study which is examining the effectiveness of low dose oral alpha interferon (LDOAI) therapy in reducing the symptoms of AIDS. Patient enrollment
(BW) (GILEAD-SCIENCES)(GILD) Gilead Commences Pivotal Phase II/III Study of GS 840 for HIV: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; FOSTER CITY, Calif.--(HealthWire)--June 5, 1996-- Gilead Sciences , Inc. (Nasdaq: GILD) announced today the commencement of a Phase II/III pivotal human clinical study of its orally administered product candidate GS 840 (adefovir dipivoxil) in patients with human immunodeficiency virus (HIV), the causative agent of AID
(BW) (UCSF/HIV-PREVENTION-2) UCSF Researchers Look At Success Of HIV Prevention Among African American Gay And Bisexual Men: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; SAN FRANCISCO--(BUSINESS WIRE)--June 3, 1996--Although there has been little research on prevention of HIV in minority gay groups, UCSF researchers are beginning to understand how HIV risk reduction efforts impact African American gay and bisexual men. African American gay and bisexual men are at substantial risk of HI
(BW) (UCSF/HIV-PREVENTION) The 15th Anniversary Of AIDS: UCSF Researchers Say Prevention Efforts Long Overdue: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; SAN FRANCISCO--(BUSINESS WIRE)--June 3, 1996--The AIDS epidemic turns 15 years old this week, and UCSF researchers say effective HIV prevention programs for those at risk, including drug users and young people, still fail to be implemented in the United States . AIDS is here to stay, said Thomas Coates, Ph.D., directo
(BW) Receptagen Published Animal Research Supports "Growth Blocker" Technology: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; EDMONDS, Wash.--(BUSINESS WIRE)--May 30, 1996--(TSE:RCG/OTCBB:RCEPF) Recently published findings show that antibodies to the vitamin B 12 receptor result in test animals failure to thrive, further supporting the theory that vitamin B 12 depletion can be used as a therapeutic approach for diseases that involve abnormal
(BW) State AIDS Program Receives Voluntary Rebate From Glaxo Wellcome: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; SACRAMENTO, Calif.--(BUSINESS WIRE)--May 30, 1996--State Health Director Kim Belshe today thanked Glaxo Wellcome for its $2.25 million voluntary rebate to California s AIDS Drug Assistance Program (ADAP). I commend Glaxo Wellcome for its generous contribution to our efforts to ensure that HIV-infected Californians have
(BW) Pharmacia Biotech AB Granted PCR License From Hoffman-Laroche And Perkin-Elmer; License Enables Pharmacia Biotech To Develop Ready-To-Go PCR Beads: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; UPPSALA, Sweden--(BUSINESS WIRE)--May 30, 1996--Pharmacia Biotech today announced that it has received a polymerase chain reaction (PCR) license from Roche Molecular Systems, Inc. and the Perkin-Elmer Corp. The license gives Pharmacia Biotech the rights to manufacture and sell Taq DNA polymerase and other thermostable
(BW) Ciba-Geigy Moscow Rep Buys Saliva Diagnostic Rapid HIV Test; Russian Military Also Interested, Says SDS President: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; VANCOUVER, Wash.--(BUSINESS WIRE)--May 30, 1996--Dr. Djhalil Memetov, Moscow representative for the Swiss pharmaceutical company CIBA-Geigy Ltd., has purchased an initial shipment of 3,000 Sero-Strip HIV-1/2 tests from Saliva Diagnostic Systems Inc. (SDS), a medical diagnostics developer and manufacturer based in Vanco
(BW) Interferon Sciences Receives U.S. Patent For Type I Interferon Receptor Protein: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; NEW BRUNSWICK, N.J.--(HealthWire)--May 30, 1996--Interferon Sciences, Inc. (NASDAQ-IFSC) announced today that the United States Patent and Trademark Office has issued a patent to the Company entitled Separation of Alpha Interferon Receptor Proteins and Antibodies Therefor (United States Patent 5,516,515). The issuance
(BW) Four European Countries Add To List Of Daunoxome Approvals; Lymphoma Data Presented At International Haematology Meeting: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; BOULDER, Colo.--(BUSINESS WIRE)--May 29, 1996--NeXstar Pharmaceuticals, Inc., (NASDAQ:NXTR) announced today at its annual meeting that Portugal , Ireland , Greece and Bel
(BW) Advanced Plant Pharmaceuticals Enters Phase II Human Clinical Trials For AIDS And Names New President: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; WEST ORANGE, N.J.--(BUSINESS WIRE)--May 28, 1996--Advanced Plant Pharmaceuticals Inc. (OTC Bulletin Board:APPI) announced today that upon the structuring of new management, Morris Moskowitz, as the new president of the company, signed an agreement with the Albert Einstein College of Medicine of Yeshiva University ( Alb
(BW) Videoconferencing Helps Schools Share "Secrets" With Teens At Risk For HIV/AIDS; Kaiser Permanente, Pacific Bell Collaborate To Speed The Spread Of Prevention Information: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; SANTA ANA, Calif.--(BUSINESS WIRE)--May 24, 1996--In response to a White House report stating that HIV is now infecting an average of two U.S. teens every hour, Kaiser Permanente and Pacific Bell are testing the use of interactive videoconferencing to accelerate the delivery of AIDS information to California youth. On
(BW) Gilead Sciences Announces Evidence Of Antiviral Activity From Phase I/II Study Of Single-Dose Cidofovir Topical Gel Treatment Of Recurrent Genital Herpes In Immunocompetent Patients: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; FOSTER CITY, Calif.--(HealthWire)--May 24, 1996-- Gilead Sciences , Inc. (Nasdaq: GILD) announced today that data from a placebo-controlled Phase I/II clinical study of single-dose cidofovir topical gel in immunocompetent patients with recurrent genital herpes lesions showed significant evidence of antiviral activi
(BW) (ADVANCED-PLANT-PHARMA)(APPI) Advanced Plant Pharmaceuticals enters Phase II human clinical trials for AIDS and names new president: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; WEST ORANGE, N.J.--(BUSINESS WIRE)--May 22, 1996--Advanced Plant Pharmaceuticals Inc. (OTC Bulletin Board: APPI), announced Monday that, in its first step towards the formation of a new management team, the company has named Morris Moskowitz as the company s new president. Moskowitz, who developed his marketing experti
(BW) Gilead's PMPA Prevented SIV Transmission: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; FOSTER CITY, CALIF. (May 20) HEALTHWIRE -May 20, 1996-- Gilead Sciences , Inc. (Nasdaq: GILD) today announced preclinical data from two studies demonstrating that injections of PMPA reduced levels of simian immunodeficiency virus (SIV) by more than 99% or to the limits of detection and that PMPA as a topical gel provid
(BW) Laboratory Corporation Of America Announces Contract To Provide Laboratory Testing For The Confide HIV Testing Service From Direct Access Diagostics; Initial Introduction To Occur In Florida And Texas: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; BURLINGTON, N.C.--(BUSINESS WIRE)--May 16, 1996--Laboratory Corporation of America Holdings (NYSE: LH) (LabCorp(TM)) today confirmed that it is under contract with Direct Access Diagnostics (DAD), a subsidiary of Johnson & Johnson (NYSE: JNJ), to act as the designated clinical testing laboratory for DAD s home coll
(BW) Patient Enrollment Initiated In Phase I/II Clinical Trial Of Procept's Pro 2000 Once-Daily Formulation For HIV: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; CAMBRIDGE, Mass.--(HealthWire)--May 16, 1996--Procept, Inc. (Nasdaq: PRCT) today announced that the Company has initiated enrollment of patients in a new Phase I/II clinical trial in Europe to evaluate the safety and efficacy of PRO 2000 for the treatment of human immunodeficiency virus type I (HIV-1) infection. The st
(BW) Advanced Viral Research announces clinical trial: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; HALLANDALE, FLA. (April 30) BUSINESS WIRE -April 30, 1996--Advanced Viral Research Corp. (OTC:ADVR) announced today that an open label trial on 20 human patients to assess the efficacy of the company s drug Reticulose on the Human Papilloma Virus ( HPV
(BW) New treatment strategy to block HIV holds promise: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; WEST LOS ANGELES (May 1) BUSINESS WIRE -May 1, 1996--A laboratory study by researchers at the UCLA AIDS Institute and West Los Angeles VA Medical Center has found that a new drug can block infection by HIV strains associated with the killing of CD4 lymphocytes -- immune system cells destroyed in people with AIDS. Curre
(BW) Biochem and Oncogene Science Sign Agreement: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; LAVAL, QUEBEC/UNIONDALE, NEW YORK (May 1) BUSINESS WIRE -May 1, 1996--BIOCHEM PHARMA INC.(TSE, ME: BCH NASDAQ: BCHXF NASDAQ: ONCS ) A joint collaborative research, development and commercialization agreement for the discovery and development of antiviral drugs for hepatitis C and novel approaches for
(BW) NeXstar Pharmaceuticals launches DaunoXome in U.S.: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; BOULDER, COLO. (April 30) BUSINESS WIRE -April 30, 1996--NeXstar Pharmaceuticals, Inc., (NASDAQ:NXTR) announces that today it is launching DaunoXome (daunorubicin citrate liposome injection) in the United States as the only therapy for advanced HIV-associated Kaposi s sarcoma for first-line use. The Company s New D
(BW) (RIBOGENE/ABBOTT-LABS) RiboGene signs agreement with Abbott Laboratories to develop new antifungal compounds: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; HAYWARD, Calif.--(BUSINESS WIRE)--April 30, 1996--RiboGene Inc. today announced the initiation of a research and development collaboration with Abbott Laboratories aimed at developing novel antifungal compounds discovered with RiboGene s translation-targeted therapeutics technology. The agreement grants Abbott the
(BW) Sequus Pharmaceuticals' Doxil Product Feature In Nature "Product Review" Section: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335; MENLO PARK, Calif.--(BUSINESS WIRE)--April 25, 1996--According to an article by Danilo Lasic, Ph.D. appearing in a recent issue of Nature (Volume 380), sterically stabilized liposomes, such as the STEALTH(R) liposomes in a new oncology drug, DOXIL (R), show promise in terms of enhancing the effectiveness and reducing t
(BW) European CPMP Gives Positive Opinion On The Anti-HIV Treatment Epivir (3TC): BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; LAVAL, QUEBEC, CANADA--(BUSINESS WIRE)--April 23, 1996-- BioChem Pharma Inc. today announced that the European Union s Committee for Proprietary Medicinal Products (CPMP) voted on April 18, 1996 in favor of recommending the approval of Epivir (TM) (
(BW) Spirulina Extract Proven To Be Effective Against The AIDS Virus -- Report At Applied Algology Association Conference In S. Africa Authored By Researchers At Harvard, Dana-Farber And Earthrise Farms Reveals Research Breakthrough: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335; KNYSNA, South Africa--(BUSINESS WIRE)--April 17, 1996-- Scientists at an international algae conference today announced that Spirulina contains a powerful anti-viral substance effective against the AIDS virus. The water extract from Spirulina, a blue-green algae produced by Earthrise Farms, totally inhibits HIV-1 in in
(BW) Sequus Pharmaceuticals Receives Approval For Amphocil In Sweden: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335; MENLO PARK, Calif.--(BUSINESS WIRE)--April 18, 1996--SEQUUS Pharmaceuticals, Inc. (Nasdaq/NMS: SEQU) today announced that AMPHOCIL(TM) has been approved in Sweden , bringing to ten the number of countries in which AMPHOCIL has been authorized for sale. Marketing clearance for AMPHOCIL has previously been granted in
(BW) Receptagen Ltd. Develop First Water Soluble CoQ10 Formulation: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335; EDMONDS, WASH. (April 17) BUSINESS WIRE -April 17, 1996--Receptagen Ltd. (OTCBB/TSE:RBEPF;RCG) announced that its U.S. subsidiary, Ryan Pharmaceuticals, has developed two new Aqueous CoQ10 formulations in collaboration with research groups at the University of Washington and the National Research Council of
(BW) Swedish Study Shows Exceptional Performance For Fast Salv HIV Test: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335; VANCOUVER, Wash.--(BUSINESS WIRE)--April 15, 1996--A recent evaluation by the Swedish Institute for Infectious Disease Control showed excellent results in both sensitivity and specificity for Sero-Strip HIV-1/2, a rapid HIV test made by Saliva Diagnostic Systems Inc. (SDS), a medical diagnostics developer with headquar
(BW) (WINNING-AGAINST-AIDS) ADVISORY/"Winning Against AIDS" HIV/AIDS Prevention Education: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 -; ADVISORY...for Monday (April 15) WHO: Winning Against AIDS Team: National Basketball Players Association, The Golden State Warriors, Women of the NBA, Mosaic Health and local youths ages 11-15 WHAT: HIV/AIDS Prevention Education, designed to bring leaders in public health, professional basketball and young peopl
(BW) (UNIVERSAL-HEALTHWATCH) ADVISORY/Universal HealthWatch Inc. to demonstrate its rapid HIV test to embassy officials and media in wake of European HIV test crisis: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335; ADVISORY...for Monday (April 15) WHAT: Briefing for international embassy officials and media: Universal HealthWatch Inc. s Quix HIV 1&2 Sero Test, a fast, accurate and simple diagnostic tool for the detection of antibodies to Human Immunodeficiency Virus in human serum or plasma. WHY: Recent international
(BW) CDC Gives Good Grade To Saliva Diagnostic Systems HIV Test: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335; VANCOUVER, Wash.--(BUSINESS WIRE)--April 10, 1996--The Centers for Disease Control (CDC) in Atlanta has found Sero-Strip HIV-1/2, a rapid and low cost HIV antibody test developed by Saliva Diagnostic Systems Inc. (SDS), works as well as other, licensed HIV assays, and has purchased more of the tests for research in Atl
(BW) (ULTRAFEM)(UFEM) Ultrafem to proceed to clinical trials with BufferGel technology to offer women protection against AIDS; FDA has permitted BufferGel to enter Phase I clinical trials to begin in summer 1996; JHU/ReProtect, LLC receives $2 million in NIH grants for BufferGel development: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 10 April 1996; NEW YORK--(BUSINESS WIRE)--April 10, 1996--Ultrafem Inc. (NASDAQ: UFEM) announced today that the buffer technology ( BufferGel ) developed by the company s research and development partner, ReProtect, LLC, has been selected by HIVNET for funding of clinical trials to test its use as a vaginal microbicide for the preven
(BW) FDA Approves Daunoxome As First-Line Therapy For Kaposi's Sarcoma: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 9 April 1996.; BOULDER, Colo.--(BUSINESS WIRE)--April 9, 1996--NeXstar Pharmaceuticals, Inc. (NASDAQ:NXTR) announced today that the U.S. Food and Drug Administration ( FDA ) has approved the Company s anticancer drug DaunoXomeb (daunorubicin citrate liposome injection) as a first-line cytotoxic therapy for the treatment of advanced,
(BW) Sequus Pharmaceuticals Receives Approval For Amphocil In Holland: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 4 April 1996; MENLO PARK, Calif.--(BUSINESS WIRE)--April 4, 1996--SEQUUS Pharmaceuticals, Inc. (Nasdaq/NMS: SEQU) today announced that AMPHOCIL(TM) has been approved in Holland, bringing to nine the number of countries in which AMPHOCIL has been authorized for sale. Marketing clearance for AMPHOCIL has previously been granted in
(BW) Gut Reaction: New Locale For Antibody Activity: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 3 April 1996; STANFORD, Calif.--(BUSINESS WIRE)--April 3, 1996--Most antibodies do their work in the bloodstream. But others may be powerless to knock out their disease-causing foes unless the confrontation takes place inside an intestinal cell, researchers have found. The unexpected discovery suggests a novel approach for designing
(BW) Study Finds Low Rate Of Hepatitis C Virus Among Blood Donors, But Suggests More Research On Some Donors At Higher Risk: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 3 April 1996; SAN FRANCISCO--(BUSINESS WIRE)--April 3, 1996--A large study of 862,398 blood donors from five blood donation centers across the United States , has found a low overall hepatitis C virus (HCV) prevalence of 3.6 per 1,000 donors but a higher rate in some demographic subgroups.
(BW) (AIDS-MEMORIAL-GROVE) National Monument for AIDS one step closer as U.S. Congresswoman Nancy Pelosi introduces legislation to designate The Aids Memorial Grove, in San Francisco's Golden Gate Park, a National Memorial: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 3 April 1996; SAN FRANCISCO--(BUSINESS WIRE)--April 3, 1996--Congresswoman Nancy Pelosi (D-CA) introduced legislation March 28, 1996 to designate San Francisco s THE AIDS MEMORIAL GROVE (AMG) a national monument. The AMG, a 15-acre wooden basin located in San Francisco s Golden Gate Park, is the nation s first living memorial to the
(BW) Quick HIV test gets government O.K.: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 2 April 1996; VANCOUVER, WASH. (April 2) BUSINESS WIRE -April 2, 1996--A fast, easy-to-use HIV test manufactured by Saliva Diagnostic Systems Inc. (SDS) is on the company s Singapore production lines and has received a certificate of free sale from the Ministry of Health in Singapore. SDS received a copy of the certificate for Hema-
(BW) ABT Associates Wins $43 Million Project To Work On Healthcare Finance And Delivery Systems In Developing And Eastern European Nations; Five-Year Global Initiative Aimed At Implementing Policies And Practices To Improve Mortality Rates, Stabilize Population Growth And Stem The Spread Of HIV/AIDS And Other Sexually Transmitted Diseases: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 2 April 1996.; CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 2, 1996--ABT Associates Inc., a research and consulting firm, has been awarded a five-year contract valued at $43 million by the U.S. Agency for International Development (USAID) to help governments revamp and update health policies, financing, management, and delivery systems i
(BW) (MERCK-3)(MRK) Fast facts about hepatitis A - What Is It?: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 2 April 1996.; Hepatitis A (HAV) is a highly contagious virus that attacks the liver. It is the seventh most commonly reported infectious disease in the United States (behind gonorrhea, chicken pox, syphilis, AIDS, salmonellosis, and shigellosis). HAV accounts for as many as 65 percent of all viral hepatitis cases in the U.S. each ye
(BW) (MERCK)(MRK) Merck & Co. Inc. receives FDA license to market Vaqta, hepatitis A vaccine: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 2 April 1996.; WEST POINT, Pa.--(BUSINESS WIRE)--April 2, 1996--Vaqta(R) (Hepatitis A Vaccine, Inactivated), a new vaccine developed by Merck & Co. Inc. for the prevention of hepatitis A , has been licensed by the U.S. Food & Drug Administration ( FDA ).
(BW) Chiron and Ortho Diagnostic Systems Settle Litigation and Grant HIV Immunoassay License to Abbott Labs: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 1 April 1996; EMERYVILLE, Calif.--(BUSINESS WIRE)--April 1, 1996--Chiron Corp. (NASDAQ:CHIR) and Ortho Diagnostic Systems Inc., a Johnson & Johnson company, announced today that the two companies have settled litigation brought in the United States District Court for the Northern District of California by Chiron against
(BW) AMBA Biosciences Produces Human Alpha Interferon From Proprietary Cells: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 28 March 1996; PRINCETON, N.J.--(BUSINESS WIRE)--March 28, 1996--Technology Management & Funding, L.P. (TMF), a principal in emerging high- technology companies that builds equity value by leveraging corporate alliances, today announced that AMBA Biosciences, one of its biotechnology portfolio companies, has used its proprietary
(BW) (AMBA-BIOSCIENCES) AMBA Biosciences produces human alpha interferon from proprietary cells: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 28 March 1996.; PRINCETON, N.J.--(BUSINESS WIRE)--March 28, 1996--Technology Management & Funding, L.P. (TMF), a principal in emerging high- technology companies that builds equity value by leveraging corporate alliances, today announced that AMBA Biosciences, one of its biotechnology portfolio companies, has used its proprietary
(BW) Gilead Begins Phase I/II Study Of Cidofovir Topical Gel For HPV-Associated Genital Warts In Immunocompetent Patients: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 28 March 1996; FOSTER CITY, Calif.--(HealthWire)--March 28, 1996-- Gilead Sciences , Inc. (Nasdaq: GILD) announced today that it has begun a Phase I/II clinical study of cidofovir topical gel in immunocompetent patients with human papillomavirus ( HPV )-associated genital warts. The randomized, placebo-controlle
(BW) Immucell Announces Alliance To Further Develop Antibody Product Against Cryptosporidiosis: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 26 March 1996; PORTLAND, Maine--(BUSINESS WIRE)--March 26, 1996--ImmuCell Corp. (NASDAQ: ICCC, BSE: IMU) today announced a license agreement on CryptoGAM with Center for Special Immunology Inc. ( CSI ) of Fort Lauderdale, Fla. CryptoGAM is ImmuCell s hyperimmune bovine immunoglobulin preparation being tested to treat and/or prevent c
(BW) Daunoxome Demonstrates Tumor Targeting Ability: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 26 March 1996; BOULDER, Colo.--(BUSINESS WIRE)--March 26, 1996--NeXstar Pharmaceuticals, Inc., (NASDAQ:NXTR) announced today that Eric Forssen, Ph.D., Director of Pharmaceutics in NeXstar Pharmaceuticals liposomal drug delivery research group, has presented data suggesting that DaunoXome, NeXstar s liposomal formulation of the antica
(BW) Daunoxome Receives Approval In Germany, The Netherlands, Finland And Norway: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 25 March 1996; BOULDER, Colo.--(BUSINESS WIRE)--March 25, 1996--NeXstar Pharmaceuticals, Inc., (NASDAQ:NXTR) announced today that Germany , The Netherlands , Finland and Norway have granted final marketing approval for DaunoXome as a primary ther
(BW) Amgen Updates Financial Community On Clinical Development Milestones: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 25 March 1996; NEW YORK--(BUSINESS WIRE)--March 25, 1996-- Amgen (NASDAQ:AMGN) Monday said that it expects to file license applications within the next 12 months to seek U.S. Food and Drug Administration approval for three late-stage product candidates and two new indications for NEUPOGEN (R) (Filgrastim). The company further sai
(BW) New Technology Available For Cleaner Water: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 21 March 1996; SAN DIEGO--(BUSINESS WIRE)--March 21, 1996--As the debate rages on over stricter enforcement of the 1974 Safe Drinking Water Act versus limited funds available for necessary upgrades, growing public awareness and concern for our nation s drinking water is prompting an immediate need for solutions to this vital issue. W
(BW) Ambisome Gains Approval In Spain; Nexstar To Launch Drug In April: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 28 March 1996; BOULDER, Colo.--(BUSINESS WIRE)--March 28, 1996--NeXstar Pharmaceuticals, Inc. (NASDAQ:NXTR) announced today that the Spanish Ministry of Health had given clinical and pricing approval to AmBisome, the Company s liposomal formulation of amphotericin B. AmBisome, the only commercial liposomal formulation of amphotericin
(BW) FDA Panel Unanimously Recommends Approval Of Gilead Sciences' Vistide For CMV Retinitis; Vistide Is First In A New Class Of Potent, Long-Acting Antivirals: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 15 March 1996.; FOSTER CITY, Calif.--(HealthWire)--March 15, 1996-- Gilead Sciences , Inc. (Nasdaq: GILD) announced today that a U.S. Food and Drug Administration ( FDA ) advisory committee unanimously recommended approval of VISTIDE(R) ( cidofovir injection) as a treatment for
(BW) Nexstar Presents Daunoxome Data At International Cancer Meeting: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 14 March 1996.; BOULDER, Colo.--(BUSINESS WIRE)--March 14, 1996--NeXstar Pharmaceuticals, Inc., (NASDAQ:NXTR) announced today that the Company will make four DaunoXome-related presentations at the 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy in Amsterdam, The Netherlands , today and tomorrow. These reports will present d
(BW) Gilead Sciences makes VISTIDE(R) Available in France: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 12 Mar 1996.; FOSTER CITY, Calif.--(HealthWire)--March 12, 1996-- Gilead Sciences , Inc. (Nasdaq: GILD) announced today that it has made VISTIDE(R) ( cidofovir intravenous) available in France for use under an ATU Program for the treatment of relapsing
(BW) Soca Research Group Stops Enrollment In Phase II/III Study Based Upon Vistide Effectiveness In Treating CMV Retinitis: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 11 March 1996; FOSTER CITY, Calif.--(HealthWire)--March 11, 1996-- Gilead Sciences , Inc. (Nasdaq: GILD) announced today that preliminary data from an independent clinical study conducted by the Studies of the Ocular Complications of AIDS (SOCA) research group demonstrated the effectiveness of VISTIDE(R) (
(BW) Successful Use of SNX-111, in the Treatment of Severe Neuropathic Pain: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 11 Mar 1996.; PARIS--(BUSINESS WIRE)--March 11, 1996--In a paper entitled Successful Use of SNX-111, a Novel N-Type Calcium Channel Blocker in the Treatment of Severe Neuropathic Pain, the outcomes in two patients with HIV-related neuropathic pain were presented today at the 7th Annual Meeting of Neuroscience in HIV-Infection held i
(BW) Amgen's NEUPOGEN approved in U.K. to treat neutropenia in people with advanced HIV infection: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 7 Mar 1996; THOUSAND OAKS, CALIF. (March 7)-- Amgen (NASDAQ:AMGN) Thursday announced that its recombinant granulocyte colony-stimulating factor (rHuG-CSF) NEUPOGEN(R) (Filgrastim) has been approved for use in the United Kingdom as a supportive therapy to treat neutropenia in people with advanced HIV infection, enabling them to rec
(BW) AmBisome compassionate use protocol initiated: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 5 Mar 1996.; BOULDER, COLO. (March 5) BUSINESS WIRE -March 5, 1996--NeXstar Pharmaceuticals, Inc., (NASDAQ:NXTR) announced today that a compassionate use protocol for AmBisome, the company s liposomal formulation of the antifungal agent amphotericin B, has begun enrolling patients. Previously, the U.S. Food and Drug Administration
(BW) Vitrasert(TM) Implant Granted FDA Marketing Clearance: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 5 Mar 1996.; CLAREMONT, Calif.--(BUSINESS WIRE)--March 5, 1996--Chiron Vision Corporation, the ophthalmic business unit of Chiron Corporation (NASDAQ:CHIR), announced today that the U.S. Food and Drug Administration ( FDA ) has granted marketing clearance for the Vitrasert (TM) Implant, the first drug delivery system
(BW) Viragen Inc. to conduct HIV/AIDS study: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 4 Mar 1996; BUSINESS WIRE -March, 4, 1996--Viragen Inc. (NASDAQ BB:VRGN) Monday announced that it will conduct an investigational study in Florida, in collaboration with Biodoron, of Viragen s natural human alpha interferon product Alpha Leukoferon(tm) for the treatment of HIV/AIDS in hemophiliacs. Charles F. Fistel, Viragen s exe
(BW) FDA Accepts Chiron Diagnostics' Filing to Market Quantiplex HIV bDNA Viral Load Test: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 4 Mar 1996; EMERYVILLE, CALIF. (March 4) BUSINESS WIRE -March 4, 1996--Chiron Diagnostics, a business of Chiron Corporation (NASDAQ: CHIR), today announced that the United States Food and Drug Administration has accepted its filing of a Premarket Approval Application (PMA) for its quantitative HIV bDNA probe assay, the QUANTIPLEX
(BW) HIV Clinical Trial Service Expands To Include Southern California: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 1 Mar 1996; SAN FRANCISCO--(BUSINESS WIRE)--March 1, 1996--An expanded Californiawide service that provides people with HIV disease with information about all HIV-related clinical trials throughout the state, has been announced by the Community Consortium of San Francisco. Trials Search is a free community service for HIV-infected
(BW) (BIO-FLUORESCENT-TECH)(BFTI) BFTI announces successful preliminary trials paving way for next step: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 28 Feb 1996; SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Feb. 28, 1996--Bio Fluorescent Technologies Inc. (OTC BB:BFTI) (BFTI) Wednesday announced the completion of the first comparison trials that assure both the FDA-licensed test and the BFTI-supplied Virion test perform equally well on known unambiguous positive and negative samples.
(BW) (BIO-FLUORESCENT-TECH)(BFTI) BFTI announces signing of long term distribution agreement in Mexico: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 22 Feb 1996.; SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Feb. 22, 1996--Bio Fluorescent Technologies Inc. (OTC BB:BFTI) Thursday announced that it has signed a distribution agreement with Mexico City based Panamerican Enterprises, S.A. de C.V. which calls for first year minimum sales of 300,000 BIOLINE HIV 1/2 tests in Mexico, with the fir
(BW) (GENENTECH)(GNE) Genentech Announces Creation Of Genenvax To Develop AIDS Vaccine: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 20 Feb 1996.; SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 20, 1996-- Genentech , Inc. (NYSE: GNE) today announced that a new company, Genenvax, Inc. has been created to expand development of gp120, Genentech s potential vaccine for the prevention of HIV infection. Donald Francis, M.D., D.Sc., a pioneer in AIDS virology and pr
(BW) Sequus Announces Unanimous CPMP Recommendation For Doxil In Europe: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 15 Feb 1996.; MENLO PARK, Calif.--(BUSINESS WIRE)--Feb. 15, 1996--SEQUUS Pharmaceuticals, Inc. (Nasdaq/NMS:SEQU) today announced receipt of a unanimous opinion from the European Committee on Proprietary and Medicinal Products (CPMP) recommending marketing authorization, in the 15 member states of the European Union (EU), of the Comp
(BW) (SEQUUS-PHARMACEUTICALS)(SEQU) Sequus Pharmaceuticals Receives Approval For AMPHOCIL in the Czech Republic: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 14 Feb 1996.; MENLO PARK, Calif.--(BUSINESS WIRE)--Feb. 14, 1996--SEQUUS Pharmaceuticals, Inc. (NASDAQ/NMS:SEQU) today announced that AMPHOCIL has been approved in the Czech Republic , the eighth country to formally approve the drug. Marketing clearance for AMPHOCIL has previously been granted in Bra
(BW) (OCTAMER) Octamer, Inc. receives four new patents; A novel possible solution for AIDS: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 14 Feb 1996.; MILL VALLEY, Calif.--(BUSINESS WIRE)--Feb. 14, 1996--Octamer is pleased to announce that the U.S. Patent and Trademark Office has recently awarded Octamer four patents which cover a new class of anti-tumor and anti-retroviral agents recently discovered in Octamer s laboratories. This new class of drugs inhibit tumor ce
(BW) (BIO-FLUORESCENT-TECH)(BFTI) BFTI begins head to head comparisons: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 12 Feb 1996.; SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Feb. 12, 1996--A division of Corning Metpath has agreed to perform a head to head comparison between the FDA approved Waldheim IFA test for HIV 1/2 and a test supplied by BFTI (produced by Virion). This test will be conducted and interpreted by one of the most highly regarded researc
(BW) Advanced Peptides Initiates Joint Development Project With Macrochem: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 8 Feb 1996.; STONY BROOK, N.Y.--(HealthWire)--Feb. 8, 1996--Advanced Peptides and Biotechnology Sciences, L.L.C., (ADVANCED PEPTIDES) today announced an agreement with MacroChem (NASDAQ: MCHM) to initiate a joint development project for delivery of Peptide T to treat psoriasis with MacroChem s SEPA transdermal drug delivery technol
(BW) Lifetech Scientists To Present Three Abstracts At Congress Of The International Society For Analytical Cytology - April 13 - 18, 1996: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 08 Feb 1996.; TORONTO--(BUSINESS WIRE)--Feb. 8, 1996--LIFETECH CORPORATION (CANADIAN DEALING NETWORK:LFTK) LifeTECH Corporation, a biotechnology company developing and commercializing proprietary technology for blood sterilization, announced today that the Congress of the International Society for Analytical Cytology has accepted th
(BW) Gilead Commences Human Clinical Testing Of GS 930 A New Antiviral Compound With Broad-Spectrum Activity: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 03 Feb 1996.; FOSTER CITY, Calif.--(HealthWire)--Feb. 8, 1996-- Gilead Sciences , Inc. (NASDAQ: GILD) announced today the commencement of clinical testing of GS 930, an antiviral drug candidate that has demonstrated activity in preclinical studies against a broad spectrum of herpesviruses, including
(BW) Chiron Viagene And Virus Research Institute Collaborate On Intracellular Gene Therapy: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 02 Feb 1996; SAN DIEGO and CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 6, 1996-- Chiron Viagene, a business of Chiron Corporation (NASDAQ: CHIR), and the Virus Research Institute (VRI) announced today that they have agreed to collaborate on the research and development of intracellular immunizing agents for human immunodeficiency virus
(BW) Gilead Sciences Announces Statistically Significant Anti-HIV Activity Of GS 840: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 31 Jan 1996.; FOSTER CITY, Calif.--(HealthWire)--Jan. 31, 1996-- Gilead Sciences , Inc. (Nasdaq: GILD) announced today the presentation of data from a randomized, double-blind, placebo-controlled Phase I/II clinical study of GS 840 (adefovir dipivoxil) for the treatment of patients with human immunodeficiency virus (HIV), the causat
(BW) (CHIRON/RETROVIRUSES)(CHIR) HIV plasma viral load most accurate predictor of survival, study determines: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 30 Jan 1996.; WASHINGTON--(BUSINESS WIRE)--Jan. 30, 1996--Viral load, the amount of human immunodeficiency virus (HIV) RNA in the plasma of infected individuals, is a better predictor than CD4+ T-cell counts of how quickly people with HIV infection will progress to AIDS and, ultimately, of their survival, according to a study presen
(BW) City of Hope awarded $4.5 million grant to investigate gene therapy treatment for AIDS: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 29 Jan 1996.; DUARTE, Calif.--(HealthWire)--Jan. 29, 1996--City of Hope National Medical Center and Beckman Research Institute has received a four-year, $4.5 million grant from the National Institute for Allergy and Infectious Diseases (NIAID) to investigate a gene therapy treatment for the human immunodeficiency virus (HIV), the vi
(BW) (GILEAD-SCIENCES)(GILD) Gilead Sciences Announces Topical Cidofovir has Statistically Significant Treatment Effect in Healing Refractory Herpes Lesions in Patients with AIDS: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 29 Jan 1996.; FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 29, 1996-- Gilead Sciences , Inc. (Nasdaq: GILD) announced today that results from a randomized, double-blind, placebo-controlled Phase I/II clinical study of cidofovir topical gel demonstrated a statistically significant treatment effect in the healing of refractory
(BW) Gilead Sciences Announces Further Results Indicating Vistide Delays Time To Disease Progression In Patients With Relapsing Cmv Retinitis: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 28 Jan 1996.; FOSTER CITY, Calif.--(HealthWire)--Jan. 28, 1996-- Gilead Sciences , Inc. (Nasdaq: GILD) announced today the presentation of interim data from 100 patients in a randomized, controlled pivotal study indicating that treatment with VISTIDE(TM) ( cidofovir intravenous) delayed time to diseas
(BW) Saliva Diagnostic Systems Signs China Distributor For HIV Tests: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 26 Jan 1996.; VANCOUVER, Wash.--(BUSINESS WIRE)--Jan. 26, 1996--China s largest importer of HIV tests has signed a contract to sell Sero-Strip HIV-1/2, a serum and plasma HIV antibody test developed by Saliva Diagnostic Systems Inc. (SDS), a medical diagnostics maker headquartered in Vancouver. Beijing Huayi Biotechnology Co. Ltd.,
(BW) Saliva Diagnostic Systems Yanks Omni-Sal From Home Access: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 25 Jan 1996.; VANCOUVER, Wash.--(BUSINESS WIRE)--Jan. 25, 1996--Saliva Diagnostic Systems Inc. (SDS), a maker of rapid medical diagnostics and sample collection devices, has acted quickly to prevent Home Access Health Corp. from making claims to rights to Omni-SAL, a saliva collection device developed by SDS. On Jan. 12, SDS filed s
(BW) Illinois Life And Health Insurance Companies Are Major Contributors To Communities In Illinois: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 24 Jan 1996.; WASHINGTON--(BUSINESS WIRE FEATURES)--Jan. 24, 1996--A new report by a life and health insurance trade group in Washington, D.C. shows that insurance companies based in Illinois were major contributors to a variety of community and charitable causes in 1994. Data from the Life and Health Insurance Industry Annual Repor
(BW) Nexstar Pharmaceuticals' Ambisome Receives First Line Approval: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 23 Jan 1996.; BOULDER, Colo.--(BUSINESS WIRE)--Jan. 23, 1996--NeXstar Pharmaceuticals, Inc., (NASDAQ: NXTR) announced today that the Australian Therapeutic Goods Administration (TGA) has approved AmBisome as a primary therapy for systemic fungal infections with candida, aspergillus and cryptococcus, and for visceral leishmaniasis. I
(BW) Medizone Appoints New Director: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 23 Jan 1996.; NEW YORK--(BUSINESS WIRE)--Jan. 23, 1996--Medizone International Inc. (OTC.BB: MZEI.U) announced today that Richard Garrett Solomon (53) has been appointed to its Board of Directors by action of the Board. His appointment increases the number of Directors to five. Dr. Joseph S. Latino, Ph.D., Medizone International Inc
(BW) (BIO-FLUORESCENT-TECH)(BFTI) BFTI expands Peruvian trials for its rapid assay tests for the detection of the HIV 1/2 viruses: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 23 Jan 1996.; SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Jan. 23, 1996--Bio Fluorescent Technologies Inc. (OTC BB:BFTI) Tuesday announced it had received a request from its distributor to expand the trials originally set up through the Peruvian Ministry of Interior for the navy department, to include the army and police departments. The tr
(BW) (GILEAD-SCIENCES-2)(GILD) Gilead Sciences Announces Completion of European Application to Market VISTIDE for CMV Retinitis: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 23 Jan 1996.; FOSTER CITY, Calif.--(HealthWire)--Jan. 23, 1996-- Gilead Sciences , Inc. (Nasdaq: GILD) announced today that the European Medicines Evaluation Agency (EMEA) has accepted the Company s application for authorization to market VISTIDE(TM) ( cidofovir intravenous) for the treatment of
(BW) (ADVANCED-VIRAL-RSRCH)(ADVR) Abstract of the effect of Reticulose on HIV submitted to the National Medical Honor Societies: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 22 Jan 1996.; HALLANDALE, Fla.--(BUSINESS WIRE)--Jan. 22, 1996--Advanced Viral Research Corp. (OTC:ADVR) is pleased to announce Receipt of Information from Dr. Hirschman that the antiviral drug Reticulose has been found to have important inhibitory effects on the human immunodeficiency virus (HIV). An abstract describing this labora
(BW) (NEUREX)(NXCO) Neurex Launches Phase III Program for SNX-111 for the Treatment of Chronic Pain: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 16 Jan 1996.; MENLO PARK, Calif.--(BUSINESS WIRE)--Jan. 16, 1996--Neurex Corporation (NASDAQ:NXCO) announced today that it had initiated its Phase II/III program with SNX-111 to demonstrate safety and efficacy in the treatment of severe and intractable pain in patients with cancer or AIDS. The pivotal, double-blind, cross-over study
(BW) (INNOVIR)(INVR) Innovir reports positive research results in Anti-Hepatitis B drug program: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 15 Jan 1996.; NEW YORK--(HealthWire)--January 15, 1996--Innovir Laboratories, Inc. (Nasdaq: INVR) today announced that several of its lead oligonucleotide-based drugs, called External Guide Sequences (EGSs) showed potent anti-viral activity against hepatitis B virus (HBV) in preclinical research. Tests conducted by Dr.
(BW) Center For Special Immunology Announces CSI Foundation Executive Director: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 11 Jan 1996.; FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Jan. 11, 1996--Center for Special Immunology Thursday announced the appointment of Alain Berrebi as executive director of its CSI Foundation for Research. The CSI Foundation for Research is a not-for-profit 501(c) corporation which was formed to support AIDS-related medical and r
(BW) Sequus Pharmaceuticals Receives Approval For Amphocil In Brazil, Denmark And Singapore: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 11 Jan 1996.; MENLO PARK, Calif.--(BUSINESS WIRE)--Jan. 11, 1996--SEQUUS Pharmaceuticals Inc. (Nasdaq/NMS:SEQU) today announced that AMPHOCIL(tm) has been approved in Brazil , Denmark and Singapore . Marketing clearance for AMPHOCIL has previously been granted in the
(BW) Xoma Corp. Chooses Lead Antifungal Compound, Mycoprex-Tm-, For Development: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 11 Jan 1996.; BERKELEY, Calif.--(BUSINESS WIRE)--Jan. 11, 1996--XOMA Corp. (NASDAQ:XOMA) today announced an important step forward in its antifungal drug development program. The company has selected a lead compound and several alternates to move from the research phase into an intensive process of product development. XOMA s goal i
(BW) Procept Initiates New Phase I/II Clinical Trial For Pro 2000 In HIV-Positive Patients: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 9 Jan 1996.; CAMBRIDGE, Mass.--(Health Wire)--January 9, 1996--Procept, Inc. (Nasdaq: PRCT) today announced that the Company has received approval to initiate a new Phase I/II clinical trial to evaluate the safety and efficacy of PRO 2000 for the treatment of human immunodeficiency virus type I (HIV-1) infection. The study will use
(BW) ( BW)(CA-DEPT-HEALTH/HIV) State Health Department's most aggressive HIV prevention media campaign hits airwaves: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 08 Jan 1996.; SACRAMENTO, Calif.--(BUSINESS WIRE)--Jan. 8, 1996--The California Department of Health Services (CDHS) most aggressive campaign to date to reduce the spread of HIV hit the airwaves today on television and radio stations throughout the state. The three-year advertising, marketing, and community relations campaign will f
(BW) Chiron Announces Preliminary Results From Genital Herpes Immunotherapy Trial: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 08 Jan 1996.; EMERYVILLE, Calif.--(BUSINESS WIRE)--Jan. 8, 1996--Chiron Corporation (NASDAQ: CHIR) announced today that based on a preliminary review of data from a clinical trial, an immunotherapeutic agent for genital herpes had a statistically significant benefit on several disease indicators but did not reach statistical signifi
(BW) Gilead Sciences Announces Commencement Of Topical Ophthalmic Cidofovir Clinical Study By Storz: BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - 02 Jan 1996.; FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 2, 1996-- Gilead Sciences , Inc. (Nasdaq: GILD) announced today that its collaborative partner Storz Instrument Company has commenced a Phase I human clinical study of topical ophthalmic cidofovir. This study is designed to determine the safety and pharmacokinetics of topical

This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1980, 1996. AEGiS.